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ABSTRACT
OPTIMIZING HER2 ANTIGEN PRESENTATION IN THE MHC I
By
Trisha R. Sippel
HER2 is overexpressed in some breast cancers, leading to an aggressive form of
the disease. Recent research has targeted HER2 overexpressing tumor cells through the
activation of cytotoxic T cells. To do this, HER2 antigens must be cross-presented from
the extracellular environment into the MHC I. To measure cross-presentation, a
variation of HER2 (EVI) which contains the sequence SIINFEKL was presented to
splenocytes. If the splenocytes present SIINFKEL in the MHC I, they will activate the
cytotoxic T cell line (B3Z), which is specific to SIINFEKL presented in the MHC I. In
attempt to increase cross-presentation, EVI was glycosylated by conjugation to oxidized
mannan. The glycosylated EVI demonstrated an increased cytotoxic T cells response
when compared to the non-glycosylated EVI, as measured by activation of B3Z cells
through production of β-galactosidase. The β-galactosidase production was also greater
than that seen in response to the SIINFEKL peptide itself. In another attempt to increase
cross-presentation of whole protein, antigens were mixed with commercial transfection
agents. The transfection agent PULSin was able to increase β-galactosidase production
in response to ovalbumin. This result indicates that transfection agents may be useful
for increasing cross-presentation. This study provides insights into the optimal antigenic
conditions to consider when creating a tumor vaccine against HER2.
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LITERATURE REVIEW

Human Epidermal Growth Factor Receptor 2 (HER2) is a protein receptor found
on most cells in the body (Bernhard et al., 2002). It facilitates the regulation of cell
growth and proliferation through interactions with its HER family members. When
overexpressed on the cell surface, the cell can become hyper-sensitive to growth
factors, or the receptor may become activated without binding a growth factor, causing
the cell to grow and divide out of control (Moasser, 2007a). This overexpression of
HER2 has been shown to be the cause of 25-30% of all breast cancers
(Slamon et al., 2001). Because HER2 is a self-protein, these cancer cells then go
unrecognized by the immune system, making HER2 overexpressing breast cancer an
aggressive form of the disease. The presence of HER2 overexpression has been
correlated with decreased survival and a faster progression of the disease when
compared to those with breast cancer not overexpressing HER2 (Slamon et al., 2001).
For this reason, HER2 has become a molecular target for breast cancer therapy.
In its natural form, HER2 belongs to a family of four epidermal growth factor
receptors: epidermal growth factor receptor (EGFR, HER1, erbB1), HER2
(erbB2, HER2/neu), HER3 (erbB3), and HER4 (erbB4). The HER family proteins are
transmembrane tyrosine kinase receptors which upon binding of a ligand to the
extracellular domain will undergo either heterodimerization with one of the other HER
family proteins or homodimerization with its equivalent HER family protein. This
dimerization induces transphosphorylation of the intracellular domain, activating the
1

receptor (Moasser, 2007a). Signaling molecules are subsequently able to bind the
phosphorylated tyrosine residues, activating downstream second messenger pathways
such as MAP kinase and PI3K/Akt. Both help signal the cell for proliferation and survival
(Hudis, 2007). Akt especially is involved with many pathways, acting as an initiator for
several different signals that regulate cellular functions important for the formation of
cancer cells. Some of these functions include epithelial-mesenchymal transition,
invasiveness, genome stability, cell cycle control, and angiogenesis
(Moasser, 2007a).
Of the HER family, HER2 has the strongest catalytic kinase activity, giving it the
strongest signaling capability when dimerized with other HER family proteins. Unlike
the other HER family proteins, HER2 does not contain a ligand binding domain. As a
result, its extracellular domain does not switch between an active and inactive
conformation, but instead exists in a constitutively activated conformation. When the
HER2 gene becomes overexpressed, the amplification of the receptor on the cell surface
can cause HER2 to form homodimers, which do not usually occur under normal
expression (Garret et al., 2003). With its constitutively active conformation and strong
signaling ability, overexpression of HER2 leads to increased stimulation of its signaling
pathways, resulting in uncontrolled cell proliferation and survival.
The overexpression of the HER2 protein can occur either through amplification
of the gene itself, or through deregulation of transcription within the cell
(Slamon et al., 1989). Breast cancer tumors have been found to contain anywhere from
25 to 50 copies of the HER2 gene per cell, causing a 40-100 fold increase in HER2 protein
2

expression and resulting in up to 2 million receptors on the cancer cell surface. When
HER2 is overexpressed on a cancer cell, the overabundance of growth signaling, along
with subsequent evasion of signaling control, is usually the initial cause of the cancer.
HER2 amplification is also maintained throughout disease progression and metastasis.
Therefore, HER2 amplification is a subtype of breast cancer, rather than an indication of
a later stage (Moasser, 2007a).
Initially it was proposed that a mutation in the HER2 gene could form a mutated
HER2 protein that would then be constitutively activated, causing continuous
downstream signaling of proliferation without dimerization. Using rodent models, it has
been demonstrated that a single base pair mutation causes a truncated version of the
HER2 protein that is missing the extracellular domain and is constitutively active. This
mutation has not been found in humans. It has been predicted that the human form of
the protein would require a two base pair substitution, which is much less likely to occur
than a single base pair mutation (Moasser, 2007b).
Just as HER2 is responsible for the initiation of tumorgenesis, it is also required
for the continuation of tumor growth. This dependency of the tumor on HER2
expression has been termed ‘oncogene addiction’. Without the overexpression of
HER2, the tumor cells would no longer grow out of control. Cell culture experiments
have demonstrated that the knockout of HER2 by siRNA in cancer cell lines
overexpressing HER2 results in cell death. Tumors not overexpressing HER2 however
are not responsive to HER2 knockdown (Moasser, 2007a).
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A better understanding of HER2’s transforming ability and aptitude to maintain
tumor proliferation has come with the study of cancer stem cells. These cancer stem
cells express properties similar to normal stem cells in that they are able to self renew
and also differentiate into specific cell types. They are therefore thought to be the
tumor-initiating cells, driving the uncontrolled growth of the tumor by deregulating their
self-renewal pathways. Korkaya et al. (2008) demonstrated that HER2 amplification
regulates the mammary stem/progenitor cell population to drive tumorgenesis. They
showed that HER2 overexpression on both normal mammary epithelial cells and
malignant mammary cells causes an increase in the stem/progenitor cell population as
identified by the stem cell marker aldehyde dehydrogenase (Korkaya et al., 2008).
As a result of HER2 overexpression driving tumorgenesis and invasiveness, and
the tumor’s dependence on it for survival, HER2 is an excellent target for breast cancer
therapy. One successful approach at targeting HER2 was the use of the monoclonal
antibody trastuzumab. Trastuzumab, a humanized mouse monoclonal antibody, is
derived from the combination of a murine antigen binding domain specific to HER2 with
the framework region of human IgG (Carter et al., 1992). A phase III clinical trial of the
monoclonal antibody in combination with the standard chemotherapy treatment for
breast cancer correlated to a longer time to disease progression, higher rate of objective
response, longer duration of response, and lower death rate at one year.
Women who had relapsed after chemotherapy also had a greater response when
a different chemotherapy was combined with trastuzumab compared to the new
chemotherapy alone. In addition, women who had significantly greater amplification of
4

HER2 benefited more from the addition of trastuzumab to their chemotherapy
treatment when compared to women who had HER2 overexpression to a lesser extent,
indicating the specificity of trastuzumab to inhibiting HER2 activity (Slamon et al, 2001).
After this phase III trial, Trastuzumab (more commonly known as Herceptin) was
approved by the FDA for treatment of HER2 breast cancer and is now considered a
standard therapy.
The side effect of trastuzumab treatment of greatest concern, especially in
combination with anthracycline chemotherapy treatment, is cardiac dysfunction.
Several other side effects were observed during the phase III trial; however, none were
severe enough to cause the discontinuation of treatment. Cardiac dysfunction, on the
other hand, was the cause of discontinuation for eight percent of the participants
(Slamon et al., 2001). A larger study indicated the risk of cardiotoxicity to be 4.7% in
patients receiving trastuzumab (Eisenhauer, 2001). Evidence suggests that cardiac
dysfunction, as a result of trastuzumab treatment, occurs from the presence of HER2
receptors or a related cross-reactive antigen on cardiac muscle. When patients with
HER2 positive breast cancer were treated with radiolabeled trastuzumab, myocardial
uptake was observed, followed by subsequent cardiotoxicity. The antibody therefore
was not only targeting the tumor cells, but also the myocardium (Behr, 2001).
In order to make the treatment more effective and avoid the side effect of
cardiac dysfunction, it is important to understand the mechanism behind which
trastuzumab acts on HER2. Several different mechanisms of action have been predicted
for trastuzumab. When the antibody binds the extracellular domain of HER2, it may
5

block dimerization of HER2 with any of the other HER receptors. It could also cause an
increase in the endocytotic destruction of the receptor, or prevent shedding of the
extracellular domain of HER2. Shedding of the extracellular domain has been linked to
autophosphorylation of the intracellular domain and therefore activation of the
secondary messenger pathways. It has also been suggested that binding of the antibody
to the receptor could induce the activation of cell mediated cytotoxicity which would
then lead to destruction of the cancer cell by immune effector cells (Hudis, 2007).
Understanding the mechanism by which trastuzumab works may also help
develop additional strategies for targeting HER2, especially for HER2 overexpressing
tumors that are resistant to trastuzumab. While trastuzumab has proved to have a
significant impact on treatment of HER2 overexpressing breast cancer, a relatively large
fraction of patients treated with adjuvant chemotherapy still relapse, one-third of
patients with advanced forms of the disease fail to respond, and the majority of initial
responders have disease progression within one year (Korkaya et al., 2008). In order to
increase the benefit of HER2 therapy, other methods of targeting the molecule are
being developed.
One area of focus involves the final proposed mechanism of action for
trastuzumab involving an immune effector response. Instead of using a monoclonal
antibody to target the receptor for immune destruction, attempts have been made to
develop a vaccine against HER2 through presentation of the protein to antigen
presenting cells. Not only would this method possibly target HER2 cancer cells, but it
might also create an immunological memory that could prevent relapse after the initial
6

therapy. It would have the advantage of creating an immune response to a protein
already present in the body, but only target those cells that overexpress the protein, not
those that have the protein at basal levels (Bernhard et al., 2002).
When creating a vaccine against a self-protein, such as HER2, there is concern
that an immune response will not be mounted against the antigen because the T cells
specific to the antigen presented in the vaccine would already be eliminated to avoid
self-reactivity. It was observed that patients with HER2 overexpression naturally have a
pre-existing immune response to HER2, both in the form of antibodies and T-cell
immunity, showing that not all T cells specific to HER2 have been eliminated, and
making it a possible candidate for use in a vaccine. The immune response was found
only in patients who had overexpression of HER2, and was of very low magnitude
(Bernhard et al., 2001). This pre-existing response showed no evidence of autoimmune
disease, indicating the immune response did not attack cells with basal expression of
HER2, and further supporting the development of vaccines in attempt to boost the
immunity of these patients.
Normally, to avoid self-reactivity, when a self-protein is processed there are
certain dominant antigens that are presented due to the breakdown of the protein and
combination of the peptide fragments with major histocompatibility complexes (MHCs).
These dominant antigens prevent activation of the immune system against the selfprotein. When the protein is overexpressed however, there is more protein to be
processed by antigen presenting cells and other, less dominant, peptide fragments
besides the dominant antigens are able to be presented. These other fragments can
7

then induce an immune response against the protein. This mechanism can be mimicked
through a vaccination that presents large amounts of protein to antigen presenting cells
to be processed (Bernhard et al., 2002). Since the tumor is overexpressing the protein
as well, the vaccine will specifically target the other, less dominant, fragments
presented on the tumor cell and not the dominant self antigens on normal cells.
Early results from previous vaccine attempts have shown that immunity could
not only be elicited, but remain intact after vaccinations had ended. These kinds of
vaccines may not only be used as a therapeutic agent for patients with HER2
overexpressing breast cancer, but may also to prevent remission or even the onset of
breast cancer (Bernhard et al., 2002). This suggests that the severe risk of cardiac
dysfunction related to treatment with trastuzumab could be eliminated through the use
of vaccines and that these vaccines could be used in conjunction with standard therapy
for an increased benefit.
Rohrbach et al. (2005) produced a vaccine in attempt to target delivery of the
HER2 (ErbB2) protein to professional antigen presenting cells (APCs). The vaccine
antigen was formed by producing a chimeric protein containing an ErbB2 fragment with
the extracellular domain of cytotoxic T-lymphocyte antigen-4 (CTLA-4). CTLA-4 is
normally found on T cells and specifically binds to B7 molecules on the APC surface,
aiding in internalization of the peptide. This protein was named C-ErbB2 and produced
through bacterial expression. Another variation of C-ErbB2 was engineered to also
contain the Pseudomonas exotoxin A translocation domain, which acts as a cytotoxin to
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cause cell death (C-E-ErbB2). These two vaccines were then compared to recombinant
ErbB2 (ErbB2222) as a control (Rohrbach et al., 2005).
The chimeric proteins were able to bind strongly to the antigen presenting cells
and were internalized rather quickly (the C-ErbB2 within one hour), which is an essential
step for the generation of peptide epitopes and antigen presentation. When these
peptides were injected into mice as a vaccine, the mice were able to reject tumor
formation when challenged with ErbB2 tumor cells as compared to mice vaccinated with
only PBS. Not only were they able to ward off tumors, but when re-challenged with the
tumor cells two months after vaccination the mice that received the C-ErbB2 were still
immune to tumor formation (Rohrbach et al., 2005).
This study also showed that tumor rejection was dependent on induction of CD8 +
effector cells by the protein vaccination. Mice were vaccinated with either C-ErbB2 or
C-E-ErbB2 and then injected with CD8- and/or CD4-specific antibodies to deplete these T
cell populations. When challenged with the tumor cell inoculation, tumors grew in the
mice with depleted CD8+ or CD8+ and CD4+ effector cells to an extent comparable to
mice vaccinated with only PBS. The mice with only depleted CD4 + cells however were
still able to reject tumor formation (Rohrback et al., 2005). This showed that the CD8+
cells were required for tumor rejection. It also suggested that the antigen delivered to
the APC was loaded into MHC I, since CD8+ T cells recognize antigens presented only in
MHC I.
Two important aspects of this study were the discovery that HER2 could be
presented to antigen presenting cells and used to form an immune response against
9

tumor cells overexpressing HER2, and that the antigen was being presented primarily
through MHC I, which targeted CD8+ T cells. This suggests that if the antigen could be
altered in another way to provide better uptake and presentation by the APCs, it could
have an even greater effect on targeting HER2 tumors. One possible alteration would
be the addition of glycosylated subunits to the protein.
Tan et al. (1997) showed that dendritic cells contain a mannose receptor that
can help mediate the uptake of antigens to MHC II presentation by detecting the
presence of terminal sugars such as mannose, fucose, and N-acetylglucosamine. They
showed that mannose receptor-antigen complexes were endocytosed into small coated
vesicles and then the peptide alone was transferred to larger vesicles. This suggested
the mannose receptor was necessary for internalization, but then released the peptide
upon transfer into the larger vesicle. The non-mannosylated antigens were present
directly in larger vesicles, suggesting that the non-mannosylated antigens were
internalized through a route separate from the mannosylated antigens. Both types of
antigen were then shown to be co-localized in vesicles with the MHC II (Tan et al., 1997).
In addition to the improved ability of a mannosylated protein to be internalized
compared to non-mannosylated protein, mannosylation also allows more antigen to be
presented by the cell. After the receptor complex is endocytosed, the receptor releases
its ligand so that it can be processed and transported to the MHC II. The receptor can
then be recycled so that more antigen can be bound and endocytosed from the
surroundings. The glycosylation of three different T cell peptide epitopes caused a 200-
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10,000 fold more efficient presentation of the antigen to induce proliferation of the
corresponding peptide specific T cell clone (Tan et al., 1997).
In order for the high concentration of antigen on the APC surface to have an
antitumor effect though, the antigen would need to be loaded onto MHC I so that it
could target the activation of CD8+ cytotoxic T cells that could then kill the tumor cells
and prevent the tumor from growing. Since the normal pathway for extracellular
antigens to be presented is through the MHC II molecule, cross-presentation of the
antigen peptides must occur within the cell in order to be associated with an MHC I
molecule. A study by Apostolopoulos et al. (1995) showed that the oxidation or
reduction of mannan conjugated to an antigen controlled which T cell effectors were
activated upon antigen presentation. If the mannan was oxidized, the antigen caused a
high activation of cytoxic T lymphocytes (CD8+ T cells) and a low amount of antibody
production. Reduced mannan caused the opposite, with a low activation of
T lymphocytes and a high production of antibody against the antigen produced
(Apostolopoulos et al., 1995). The antigen used in this study was the human MUC1, a
protein highly expressed in adenocarcinomas.
These results suggested that oxidation of mannan controlled which pathway the
antigen entered after endocytosis. This same group later demonstrated that the
oxidized mannan did cause the MUC1 to target the mannose receptor of dendritic cells
and enter the MHC I presentation pathway through cross-presentation
(Apostolopoulos et al., 2000). This confirmed that glycosylation of a protein to be used
as a vaccine, especially through the use of oxidized mannan, can lead to a more efficient
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presentation of the antigen peptide through the use of MHC I presentation pathway.
The presentation in MHC I would then target the activation of CD8 + cytotoxic T cells for
an immune response against cells expressing that antigen.
Burgdorf et al. (2007) showed that cross-presentation occurs specifically through
the mannose receptor on APCs and endocytosis through the mannose receptor causes
the antigen to enter a distinct processing pathway specific to presentation in MHC I.
The mechanisms of antigen uptake investigated were pinocytosis, mannose receptor
endocytosis, and scavenger receptor endocytosis. They discovered that pinocytosis and
scavenger receptor endocytosis placed the antigen in lysosomes that were then specific
for presentation in MHC II. The mannose receptor endocytosis however targeted the
antigen for early endosomes that were then specific for presentation in MHC I
(Burgdorf et al., 2007). These APCs were shown to then activate the appropriate
corresponding T cell to the MHC complex in which the antigen had been loaded. This
confirmed that mannose receptor uptake is necessary for cross-presentation of an
antigen.
Luong et al. (2007) used a different approach to show that mannose receptor
could be targeted for increased presentation of a glycosylated antigen through antigen
protein synthesis in fungi. Fungi preferentially use mannose when creating
O- and N-linked glycosylation on their proteins. Taking advantage of this, they also
showed that the type of mannosylation affected the immunogenicity of the antigen.
Ovalbumin produced in yeast cells (glycosylated) and Escherichia coli (non-glycosylated)
were presented to bone marrow dendritic cells and tested for presentation through a
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[3H]-thymidine incorporation lymphoproliferation assay of CD8+ T cells. Not only did the
mannosylated OVA cause a higher rate of proliferation of CD8+ T cells, but it was
observed that OVA containing O-linked mannosylation was more immunogenic when
compared to N-linked mannosylation (Luong et al., 2007).
Based on these findings, this project attempted to increase the efficiency of
HER2 presentation to APCs by targeting of the mannose receptor through the formation
of a glycosylated version of HER2. As suggested by previous results, glycosylation was
predicted to increase the cross-presentation of HER2, which would be presented in the
MHC I and target activation of cytotoxic CD8+ T cells. This project could provide
important insight when considering the formation of a novel immunotherapy for HER2
overexpressing breast cancer.
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METHODS

Producing EVI in E. coli:
Plating E. coli transfected with EVI:
Luria-Bertani (LB) agar plates were prepared by dissolving 25 g into 1 L distilled
water and allowed to solidify. Using a heat sterilized metal loop, a small amount of
frozen E. coli containing the plasmid EVIpTriEx was streaked onto the plate. The plate
was incubated at 37 °C overnight.

Inoculation of LB broth with E. coli:
A 25% LB broth solution was prepared and heated to a boil. After cooling to
room temperature, 25 mL of LB broth was transferred to a 125 mL flask using a sterile
pipet. One microliter of carbenicillin (100 mg/mL) per milliliter of broth and 1 μL of
chloramphenicol in 50% ethanol (34 mg/mL) per mL of broth was added to the flask. A
heat sterilized inoculating loop was used to inoculate the broth with an individual colony
from a plate of LB agar with E. coli EVIpTriEx streaked on it. The flask was then
incubated overnight at 37°C with agitation.
The next morning the overnight growth was used to inoculate 5 larger flasks.
One 2 L flask was prepared with 600 mL of LB broth and four 1 L flasks with 350 mL of LB
broth for a total of two liters. One milliliter of the growing culture was used to inoculate
each flask. The flasks were then incubated at 37 °C with agitation for 4 hrs. After
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4 hours each flask appeared cloudy and 1 μL of 1 M IPTG per mL of broth was added to
each flask. The flasks were then incubated with agitation overnight at 37 °C.

EVI inclusion body isolation:
The E. coli LB broth inoculations were transferred from the five flasks into five
500 mL centrifuge bottles. The bottles were centrifuged at 3280 x g for 15 min at 4°C in
a Sorvall RC 5B Plus centrifuge. The supernatant was removed and the pellets were
resuspended into 40 mL of Buffer A (50mM Tris, 25% sucrose, pH 8.0) with protease
inhibitors cocktail set III (Calbiochem) (1:1000 dilution) added just prior to use. The cells
were then lysed by adding 100 mL of Buffer B (20 mM Tris, 100 mM NaCl,
1% deoxycholate, 1% Triton-X, 0.3 mg/mL lysozyme, pH 8.0) per bottle, with lysozyme
(Sigma) and protease inhibitors at a 1:1000 dilution added just prior to use. The
suspensions were mixed for 15 min at room temperature. After mixing, 1 μL of
1 mM MgCl2 per mL solution and 0.02 μL of benzonase (Novagen) per mL of solution
were added to each bottle. The bottles were mixed for at least 10 more minutes or until
the viscosity visually decreased.
The solutions from the five tubes were then combined into two 500 mL
centrifuge bottles, each with equal volumes. The 500 mL bottles were then centrifuged
at 3280 x g for 15 min at 4°C. The supernatant was discarded by pipetting and the pellet
was resuspended into 25 mL of Buffer C (20 mM Tris, 100 mM NaCl, 0.5% Triton-X,
pH 8.0). More Buffer C was added until each bottle had approximately 150 mL of
suspension. Thie suspension was centrifuged at 3280 x g for 10 min at 4 °C. The
15

resulting pellet was washed two more times with Buffer C. The supernatant was again
discarded and the pellet was this time resuspended into 25 mL of Base Buffer (20 mM
Tris, 100 mM NaCl, pH 8.0). More Base Buffer was added until each tube had 250 mL
total volume. The bottles were centrifuged at 3280 x g for 10 min at 4 °C. The
supernatant was discarded and the pellet was resuspended into 10 mL Base Buffer. The
resuspended pellet was transferred to a 35 mL Oak Ridge centrifuge tube. The original
bottle and transferring pipet were washed with an additional 20 mL of Base Buffer. This
was then added to the 35 mL Oak Ridge tube. The two Oak Ridge tubes were
centrifuged at 11,000 x g for 10 min at 4 °C. The supernatant was discarded and the
pellets were stored at -20 °C in the Oak Ridge tubes until further processed.

FPLC of EVI inclusion bodies:
The pellets in the Oak Ridge tubes were resuspended into 20 mL of solubilization
buffer (20 mM Tris, 0.5 M NaCl, 6 M GuHCl, 10 mM imidazole). The tubes were mixed
for one hour at room temperature to allow for solubilization of the inclusion bodies.
The tubes were centrifuged at 17,500 x g for 10 min at 4°C. The supernatant, which
contained the solubilized E. coli proteins, was removed and filtered through a 0.22 μm
bottle top filter (Corning). This solution was then used for fast protein liquid
chromatography (FPLC).
The FPLC apparatus was prepared for purification of the EVI by first loading
100 mM sterile filtered NiSO4 into a 5 mL HiTrap chelating column (GE Healthcare). The
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column was then washed with 15 mL of solubilization buffer. Any protein in the column
was eluted by washing the column with 15 mL elution buffer (20 mM Tris,
0.5 M NaCl, 6 M GuHCl , 300 mM imidazole). The column was again washed with 25 mL
solubilization buffer while the solubilized E. coli proteins were loaded into a 10 mL loop.
After the 25 mL of solubilization buffer had run through the column, the protein solution
was pushed from the loop into the column and 10 mL samples were collected on a
fraction collector. After loading the column with protein, the column was washed with
1.5 mL of solubilization buffer while the loop was loaded with 10 additional mL of the
solubilized E. coli proteins. This was then pushed from the loop into the column. The
column was washed with another 15 mL of solubilization buffer. The buffer was
changed to a 20 mM imidazole solution (a mixture of 3.5% elution buffer and 96.5%
solubilization buffer) and the column was washed with 15 mL. A fraction collector was
used to collect 1.0 mL samples of the 20 mM imidazole column elution during this time.
The column was washed with 15 mL elution buffer (300 mM imidazole) to elude the EVI
off the column while continuing to collect 1 mL fractions. An addition 15 mL
solubilization buffer was pushed through the column.
During the FPLC, a chromatograph was obtained, showing the absorbance at
280 nm of the solution eluted from the column and collected by the fraction collector.
The peaks on the chromatograph indicate fractions containing protein. The fractions
were then combined into groups containing protein from the different steps in the
procedure: flow through (proteins that did not stick to the column, but flowed through
when the protein solution was injected into the column), 20mM imidazole fraction
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(from the mixture of solubilization and elution buffers that would elute loosely bound
proteins), 300mM imidazole fraction (from washing with elution buffer, which should
elute the tightly bound EVI protein), and after flow (from the last wash with
solubilization buffer). Samples from all groups were subjected to SDS-PAGE gel
electrophoresis to assure the EVI was primarily in the 300 mM imidazole fraction.

Gel Electrophoresis of FPLC fractions:
The FPLC fractions were prepared for gel electrophoresis using a protocol to
remove the 6 M GuHCl from the proteins. One hundred microliters of the sample was
mixed with 900 μL of 100% ethanol at -20 °C. This was placed at -20 °C for 10 min. It
was then centrifuged at 7,200 x g in a table top centrifuge for 8 min. The supernatant
was carefully removed using a fine tip pipet. The pellet was resuspended into 1 mL of
90% ethanol at -20 °C and vortexed briefly. This suspension was incubated at -20 °C for
5 min and centrifuged as described for 8 min. The supernatant was again carefully
removed. The pellet was allowed to air dry for 5 min and resuspended into 65 μL
distilled water, 10 μL 500mM DTT, and 25 μL LDS-PAGE buffer (Invitrogen) for a total
volume of 100 μL. Each sample was heated at 70-80 °C for 10-15 min.
The samples were loaded onto an 8% Tris-Glycine gel (Invitrogen) in a gel box
filled with MOPS-SDS buffer (Invitrogen). After the wells were loaded, 500 μL of
NuPAGE antioxidant was added to the upper chamber of the gel box, moving the tip
across the chamber as it was expressed. The gel ran for 30-35 min at 200 volts. The gel
was removed from the boxed and stained with Simply Blue Safe Stain (Invitrogen) with
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agitation overnight. The gel was de-stained with distilled water for several hours, and
archived using cellophane sheets and Dry-ease solution (Invitrogen).
Fractions containing EVI were identified by the presence of a well defined band
on the gel at around 56,000 Daltons based on protein standards. The fractions
containing EVI were combined and prepared for refolding and dialysis.

Estimating protein concentration:
Before dialysis, the combined fractions were tested to estimate their protein
concentration using a spectrophotometer. A sample of the combined fractions was
diluted 1:10 by mixing 900 μL of solubilization buffer in a cuvet with 100 μL sample.
Using solubilization buffer as the blank, the absorbance of the sample was taken at
280 nm. The approximate concentration of the sample was then calculated, based on a
protein solution with an absorbance of 0.682 at 280 nm having a concentration of 1 g/L.

Dialysis of FPLC fractions/EVI sample:
The combined fractions to be refolded were diluted with Diluent Buffer (20 mM
Tris, 6 M Guanidine HCl, 0.5 M NaCl, 2 mM EDTA) to a concentration of 0.3 mg/mL
sample in 12 mL total volume. Prior to refolding, DTT was added to the sample to a final
concentration of 2 mM in a total volume of 3 mL. For example, when the approximate
concentration of the protein was 1.5 mg/mL a volume of 2.4 mL was required for a
concentration of 0.3 mg/mL in 12 mL. Therefore, the 2.4 mL of sample was first mixed
with 6 μL 1M DTT, and 594 μL diluent buffer. This mixture was incubated at 37°C for
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30 min. After the incubation, 9 mL of diluent buffer was added to the mixture, bringing
the total volume to 12 mL. The sample was then chilled to 4 °C.
The 12 mL sample was injected into a Slide-A-Lyzer Dialysis Cassette (Pierce) with
an 18 g needle according to the manufacturer’s protocol. The cassette was placed in a
float and allowed to dialyze overnight at 4 °C while spinning in renaturation buffer (100
mM Tris, 0.5 M Arginine, 2 mM EDTA, pH 8.0). The buffer was then switched to fresh
renaturation buffer and the sample was allowed to dialyze for nine additional hours.
The buffer was switched to a phosphate buffered saline (PBS) solution and left to dialyze
overnight. The solution was then switched to a fresh PBS solution and allowed to
dialyze for an addition eight hours. The EVI solution was removed from the dialysis
cassette using an 18 g needle and placed into a sterile 15 mL centrifuge tube. This was
stored at 4 °C until the solution was ready to be quantified and concentrated.

Quantifying protein solution:
The concentration of the EVI protein solution, now refolded and in PBS, was
found using the Qubit flurometer (Invitrogen) according to the manufacturer’s protocol.
Four samples were prepared, three standards and one sample of the EVI solution. First,
Quant-iT Reagent was diluted 1:200 into Quant-iT buffer to make the Quant-iT working
solution. Each sample was then diluted 1:20 in the working solution. The standard
samples prepared were at protein concentrations of 0, 200 and 400 μg/mL. Each
sample was incubated at room temperature for 15 min. The Qubit was calibrated using
the standard samples prepared. The QF value of the EVI sample was then found using
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the Qubit flurometer and used to calculate the concentration of the EVI solution
according to the following equation:
Concentration of sample = QF value x 200
X
(where X is the volume in μL of the EVI sample diluted in working
solution)

Concentrating protein solution:
The EVI solution was concentrated using an Amicon Ultra-15 Centrifugal Filter
Device (10,000 MWCO). The filter device was rinsed with PBS prior to centrifugation of
the sample by adding 4 mL of PBS to the filter and centrifuging for 15 min at ¾ max
speed on the Fisher Scientific Centrific centrifuge with a swinging bucket rotor. Any PBS
remaining in the filter device was then discarded and the sample was added to the top
of the filter device. The sample was centrifuged at ¾ max speed for 15 min intervals
until the volume remaining in the top of the filter device approached 1.5 mL. It was
then centrifuged at ¾ max speed for 5 min intervals until there was about 1.0 mL
remaining in the device. This was then transferred to a 5 mL syringe and filtered
through a 0.22 μm filter into a 1.5 mL sterile tube. The concentration of the EVI was
calculated based on the starting concentration, starting volume, and the final volume of
the solution. The EVI was then stored at -20°C until it was used as an antigen in the B3Z
assay.

21

B3Z Assay using RPMI media:
Splenocyte preparation in RPMI:
The spleen was removed from a C57BL/6 mouse using aseptic techniques and
placed into a 10 mL of Roswell Park Memorial Institute (RPMI) 1640 medium. In a
class II biosafety cabinet, two frosted tip microscope slides sterilized in 70% ethanol and
washed with sterile PBS were used to homogenize the spleen into the 10 mL of medium,
using the rough side of the frosted tips. The medium was transferred to a 15 mL
centrifuge tube. The plate was washed with an additional 5 mL of medium, which was
added to the 15 mL centrifuge tube. The tube was centrifuged at 1250 rpm in an
International Equipment Company Model HN-S centrifuge for 5 min. The supernatant
was aspirated and the pellet was resuspended into 1 mL of red blood cell lysing buffer
(Sigma). After a one minute incubation in the red blood cell lysing buffer, 14 mL of RPMI
medium were added to the tube. The tube was centrifuged at 1250 rpm for 5 min. The
supernatant was aspirated and the pellet was resuspended into 7 mL of complete RPMI
medium (10% FBS, 1% L-glutamine, 1% kanamycin, 1% NEAA, 1% sodium pyruvate, 1%
HEPES, 0.1% 2-β-mercaptoethanol, 0.22 μm sterile filtered). The cell suspension was
transferred to a 25 cm2 cell culture flask and incubated for 4-5 hours at 37 °C and
5% CO2.

Cell counting:
After the 4-5 hour incubation, splenocytes adhering to the plastic were counted
using a hemocytometer as described in Barker (1998). The B3Z cells were also counted
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in the same fashion before adding them to the plate with the antigen and splenocytes.
The cells were prepared for counting by aspirating off the medium in the culture flask
and adding 10 mL of new medium to the flask. The flask was scrapped using a cell
scraper. The cell suspension was then transferred to a 15 mL centrifuge tube. The
suspension was mixed briefly by inverting the tube. A 40 μL sample was taken from the
cell suspension and mixed with 40 μL of trypan blue (Gibco). The mixture was pipetted
onto the hemocytometer and the cells located in the four outer 5 x 5 corner squares
were counted. The concentration of the cells in the suspension could then be calculated
according to the following equation:
Cell concentration = # cells counted on hemocytometer x 2 x 10,000
4

The cell suspension in the 15 mL centrifuge tube was centrifuged in an IEC Model
HN-S centrifuge at 1250 rpm for 5 min. The medium was aspirated off and the pelleted
cells were resuspended into the correct volume of medium so that the B3Z cells would
have a final concentration of 1.4x106 cells/mL and the splenocytes would have a
concentration of 2.6x106 cells/mL.

Plate set-up:
A 96 well plate was set up with a serial dilution of antigen, starting with the
highest concentration in row A. The antigen was diluted to the highest concentration in
PBS, to a total volume of 200 μL. The wells in rows B-H were then filled with 100 μL of
PBS. The serial dilution was started by taking 100 μL from row A and mixing it with the
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100 μL of PBS in row B. This was continued through row G. Row H was then left with
only 100 μL of PBS as a negative control. Each well had 50 μL of splenocyte cell
suspension and 50 μL of B3Z cell suspension at the concentrations listed above added.
The plate was incubated for 24 hours at 37 °C and 5% CO2 before preparing it for a
β-galactosidase luminescent reading.

B3Z Assay super-activating splenocytes:
Splenocyte Preparation in AIM-V medium:
Splenocytes prepared in AIM-V medium were initially isolated in the same
process as described for the RPMI preparation. The only difference in the procedure
was to use AIM-V medium throughout the process and then complete serum free AIM-V
medium (1% L-glutamine, 1% Penicillin-Streptomycin, 1% NEAA, 1% Sodium Pyruvate,
1% HEPES, 0.1% β-mercaptoethanol, 0.22 μm sterile filtered) for the final resuspension
before transferring the splenocytes to the culture flask for incubation.

Plate set-up:
The B3Z assay using AIM-V and Iscove’s Modified Dulbecco’s Medium (IMDM)
was set up using the same serial dilution of antigen as described in the B3Z assay using
RPMI medium. Each well containing antigen and PBS had 5 μM ionomycin added to it.
Finally, 100 μL of splenocytes at a concentration of 1.3x106 cells/mL in complete serum
free AIM-V medium was added to each well. The plate incubated for 48 hours at 37 °C
and 5% CO2.
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The plate was prepared for the addition of B3Z cells by centrifuging at 1250 rpm
for 5 min in an IEC Model HN-S centrifuge. The cells were washed twice with 100 μL of
IMDM medium. After centrifuging the plate again for 5 min at 1250 rpm, the
supernatant was aspirated off the cells were resuspended into 100 μL complete IMDM
medium (10% FBS, 1% penicillin-streptomycin, 1% NEAA, 1% sodium pyruvate,
1% L-glutamine, 1% HEPES).
B3Z cells in complete IMDM medium were then counted as described above, and
100 μL of the B3Z cell suspension at a concentration of 7.0x10 5 cells/mL was added to
each well containing 100 μL splenocytes in complete IMDM medium. The plate was
then incubated for an addition 24 hours at 37 °C and 5% CO2 before preparing it for a
β-galactosidase luminescent reading.

β-galactosidase Luminescent readings:
The plate was prepared for a luminescent reading by centrifuging for 5 min at
1250 rpm. The supernatant was discarded and the cells were washed with 200 μL of
PBS. This process was repeated one more time. Into each well was added 50 μL of
Mammalian Protein Extraction Reagent (MPER) (Pierce). The plate was shaken gently
on a microplate shaker for 5 min. The Clontech Luminescent β-galactosidase detection
kit II reaction solution was prepared by diluting the reaction substrate 1:50 into the
reaction buffer. The β-galactosidase reaction solution was allowed to warm to room
temperature.
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After shaking for 5 min, β-galactosidase positive control (Clontech) was added to
the plate. The β-galactosidase positive control was first diluted 1:2000 into PBS. This
was diluted further, 1:5, into PBS. The final dilution was used to start a serial dilution of
β-galactosidase positive control by placing 100 μL of the final dilution into well A12 on
the plate. Wells B12-H12 were filled with 50 μL of PBS. The dilution was started by
taking 50 μL from well A12 and mixing it into well B12. The serial dilution was continued
through well G12. Well H12 contained only PBS.
The β-galactosidase reaction solution was added to the plate by dispensing
150 μL into each well containing 50 μL of cells in MPER and each well containing the βgalactosidase positive control. The plate was incubated for 1 hour at room
temperature. The plate was then read using a GloRunner microplate luminometer
(Turner Biosystems) and the GloRunner DXL software or the Modulus Microplate Reader
(Turner Biosystems).

Fixing Splenocytes with Glutaraldehyde:
Splenocytes isolated into AIM-V media, as described previously, were incubated
for 4 hrs at 37°C and 5% CO₂. A 96 well plate was set up with serial dilutions of antigen
as described for the B3Z assay using RPMI. The splenocytes were allowed to incubate
with the antigens for 15 min at 37°C and 5% CO₂. After 15 min, half the wells containing
splenocytes at each antigen concentration were fixed with glutaraldehyde, as described
by Hosken et al. (1989). Glutaraldehyde was prepared fresh by diluting to a final
concentration of 2% in Hank’s buffered salt solution (HBSS). This was added to the
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splenocyte cell media in each well to a final concentration of 0.05%. The plate was then
incubated for one hour at 37 °C and 5% CO₂. B3Z cells were then added to the plate in
IMDM media as described for the super-activating method and the plate incubated for
an additional 4 hours at 37 °C and 5% CO₂ before preparing for a β-galactosidase
luminescence reading.

Activating B3Z cells with PMA/ionomycin:
To directly assay for β-galactosidase production in the B3Z cells, phorbol 12myristate 13-acetate (PMA) and ionomycin were used to activate the B3Z cells as
described by Karttunen et al. (1992). A 96 well plate was set up with a serial dilution of
PMA and ionomycin, starting with 10 ng PMA and 5 μM ionomycin as the highest
concentration. B3Z cells (100 μL) were then added to each well at a concentration of
7.0x105 cells/mL in either complete IMDM media, complete RPMI, or cells that had been
switched from complete RPMI to IMDM media. The plate was incubated at 37 °C and
5% CO₂ for 4 hrs before preparing for a β-galactosidase luminescence reading.

Enzyme Linked Immunosorbant Assay (ELISA) of splenocytes:
To assay for SIINFEKL presentation in the MHC I without using the B3Z cells, an
ELISA was conducted on the splenocytes alone. Splenocytes were isolated into
complete serum free AIM-V media as described previously. A 96 well plate was set up
with a serial dilution as described for the B3Z assay with RPMI. Splenocytes

27

(100 μL) were added to the plate and allowed to incubate for 48 hrs at 37 °C and 5%
CO₂. The plate was centrifuged at 1250 rpm and the supernatant discarded. The
splenocytes were fixed by adding 200 μL of 4% formaldehyde to each well and
incubating at room temp for 10 min before discarding the formaldehyde. Each well was
rinsed three times with 200 μL PBS. The wells were blocked by washing with goat serum
diluted 1:20. The goat serum (100 μL) was added to each well, and incubated for 5 min
at 37 °C and 5% CO₂ before washing two times with 100 μL PBS. This blocking process
was repeated two more times. One hundred microliters of the primary antibody
(25-D1.16, anti-mouse MHC I bound to the peptide SIINFEKL, diluted 1:1000) was added
to each well. The plate incubated 60 min at 37 °C and 5% CO₂.
The plate was washed three times with 100 μL PBS, before adding 100 μL of
horseradish peroxidase Avidin D (diluted 1:500) to each well. This incubated 60 min at
37 °C and 5% CO₂. The plate was again washed three times with 100 μL PBS. The
secondary antibody was detected using the Thermo Scientific Super Signal ELISA Pico
Chemiluminescent Substrate according to the manufacturer’s protocol. The substrate
(100 μL) was added to each well. The plate was mixed for one minute on a plate shaker.
The luminescence was read on the Modulus Microplate Reader (Turner Biosystems).

Immunofluorescence of B3Z cell T cell Receptor:
Plating B3Z cells:
A 24 well plate was set up with BD BioCoat Poly-L-Lysine 12 mm round coverslips
(BD Biosciences) in wells 1 and 2 of rows A and B. The wells were washed with
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70% ethanol and then PBS. Two flasks of B3Z cells (one with the old cells that had been
in culture in the lab for over a year and the other with the new B3Z cells received from
the University of California at Berkeley, courtesy of Dr. Nilabh Shastri) were scraped and
transferred to a 15 mL centrifuge tube. The cells were centrifuged for 5 min at
1250 rpm. The supernatant was discarded and the cell pellets were resuspended into
10 mL of complete RPMI. Depending on the size of the pellet formed, either 150 μL or
300 μL of cell suspension was added to the wells containing the round cover slips. The
final volume in each well was brought to 1 mL with complete RPMI media. The plate
was incubated overnight at 37 °C and 5% CO₂.

Measuring Immunofluorescence:
The media was aspirated from each well and 1 mL of 4% formaldehyde was
added to fix the cells to the cover slips, incubating for 10 min at room temperature. The
formaldehyde was aspirated and the wells were rinsed twice with 1 mL PBS. The wells
were blocked with goat serum by adding 25 μL of goat serum to each well, incubating
for 5 min at 37 °C and 5% CO₂, and washing twice with 1 mL BD Pharmigen staining
buffer (BD Biosciences). This blocking procedure was repeated two more times. The
primary antibody, a mouse monoclonal antibody specific to TCRα and TCRβ (Abcam),
was diluted 1:100 in staining buffer and 25 μL was added to each well. The plate was
incubated for one hour at 37°C and 5% CO₂.
Each well was washed three times with 1 mL staining buffer over a period of
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5 min. The secondary antibody, biotin conjugated anti-mouse IgG (BD Biosciences), was
diluted 1:50 in staining buffer and 25 μL was added to each well. The plate was
incubated for an additional hour at 37 °C and 5% CO₂. The wells were washed three
times with 1 mL staining buffer over 5 min.
The plate was taken into the darkroom and all subsequent steps were done in
the dark. Streptavidin-FITC (BD Biosciences) was diluted 1:25 in staining buffer and
25 μL was added to each well. Each cover slip was removed from the well and mounted
onto a microscope slide with a drop of Vectasheild mounting medium with DAPI (Vector
Laboratories). The slides were visualized using an Olympus BX51 Fluorescent Microscope.

Glycosylating Antigens with Oxidized Mannan:
The antigen proteins were glycosylated with oxidized mannan as described by
Apostolopoulos et al. (1995). Mannan (Sigma) was dissolved to 14 mg/mL in PBS with
0.01 M sodium periodate and incubated for 60 min at 4 °C. Ethylene glycol (10 μM) was
then added to the solution and incubated an additional 30 min at 4 °C. A HiTrap Q
Sepharose HP column (GE Healthcare) was equilibrated with 0.2 M sodium
carbonate/biocarbonate buffer, pH 9.0. The first 2 mL of void volume was collected.
This was mixed with 900 μg of antigen and allowed to incubate overnight at room
temperature. Electrophoresis performed using the non-glycosylated and glycosylated
antigens to see if the band for the glycosylated antigen migrated more slowly down the
gel due to the added molecular weight of the conjugated mannose.
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Protein Transfection Agent delivery of antigens:
TransPass-P protein transfection agent:
Splenocytes were isolated as described previously into serum free AIM-V media.
A 96 well plate was set up with 100 μL of splenocytes at a concentration of
1.3x106 cells/mL. The antigens were mixed with the transfection agent TransPass-P
(New England BioLabs) as described by the manufacturer. Each antigen was diluted to
10 μM in serum free AIM-V to a total volume of 30 μL with 0.6 μL TransPass-P. This was
incubated for 20 min at room temp before adding 10 μL of the transfection mix to each
well containing splenocytes. The plate was incubated at 37 °C and 5% CO₂ for 4 hrs. B3Z
cells were added to the plate in IMDM media as described for the super-activating
splenocytes procedure. The plate was incubated for an additional 24 hrs at 37 °C and
5% CO₂ before preparing for a β-galactosidase luminescent reading.

PEI (jetPRIME) DNA transfection agent:
Splenocytes were isolated into complete RPMI media as described previously. A
96 well plate was prepared by adding 100 μL of splenocytes at a concentration of
1.3x106 cells/mL to each well. Each antigen was diluted to a concentration of 1 μg/mL in
PBS. To make the transfection mixes, 2 μL of diluted antigen, 4 μL jetPRIME (Polyplustransfection) and 100 μL jetPRIME buffer were mixed together and incubated at room
temperature for 10 min. Five microliters of the transfection mix was then added to a set
of wells containing splenocytes. The plate was incubated overnight at 37 °C and 5% CO₂.
B3Z cells in complete RPMI (100 μL) were then added to the plate at a concentration of
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7.0x105 cells/mL. The plate was incubated an additional 24 hrs at 37 °C and 5% CO₂
before preparing it for a β-galactosidase luminescent reading.

PULSin protein transfection agent:
Splenocytes were isolated into complete RPMI as described previously. Before
adding the cells to the plate, they were washed with complete serum free RPMI to
remove serum. The splenocytes were then resuspended into complete serum free RPMI
media. A 96 well plate was prepared by adding 100 μL splenocytes at a concentration of
1.3x106 cells/mL to each well. To make the transfection mixes, 2 μL of antigen diluted to
1 μg/mL, 4 μL PULSin transfection agent (Polyplus-transfection) and 100 μL 20mM
HEPES buffer were mixed together and incubated at room temperature for 15 min. Ten
microliters of transfection mix was added to a set of wells with splenocytes. The plate
incubated overnight at 37 °C and 5% CO₂. The plate was centrifuged at 1250 rpm and
the supernatant was aspirated off. B3Z cells in complete RPMI media were added to the
plate at a concentration of 3.5X105 in 200 μL. The plate incubated for 24 hours at 37 °C
and 5% CO₂ before it was prepared for a luminescent reading.

Statistics and Data presentation
Unless otherwise noted, all β-galactosidase luminescent readings are reported as
the luminescence value measured for the variable in question with luminescence value
of the respective control subtracted from it. The zero line on each graph therefore
depicts the luminescence measurement for the respective control. For example, in the
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super-activation with ionomycin assays, the luminescence value reported for EVI at each
concentration would be the luminescence value measured for EVI on the microplate
reader with the luminescence value for the ionomycin control subtracted from it.
Statistical difference was then determined by comparing the original measurement for
the variable (that did not have the control subtracted from it) and the measurement for
the control using a student t-test, with p < 0.05 considered significant.
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CHAPTER 1: B3Z ASSAY USING THE RPMI METHOD

Introduction
Antigen presenting cells of the immune system have two ways of processing
foreign materials to initiate an immune response. External antigens, such as cellular
debris from infection or tissue damage, are endocytosed and placed into lysosomes.
Here the antigen is cleaved into smaller peptides. MHC II molecules produced in the
Endoplasmic Reticulum (ER) are transported to the lysosome, where they bind the
peptides. This peptide/MHC II complex is then presented on the cell’s surface. Internal
antigens found in the cytosol, most of which are endogenous to the cell or a result of
viral infection, are cleaved by proteosomes in the cytosol. These peptides are then
transported into the ER, where they form complexes with an MHC I molecules. The
complexes are then transported to the cell surface for presentation
(Raghavan et al., 2008).
Peptides presented in an MHC II activate T helper cells, which produce specific
cytokines that in turn activate B cells to produce antibodies specific to the peptide that
was originally presented in the MHC II. Antigens presented in the MHC I activate
cytotoxic T cells, which will then act to destroy any cell displaying the original peptide
(Raghavan et al., 2008). This process can be beneficial in the case of tumor antigens. If
cytotoxic T cells could be activated to attack tumor antigens found on cancer cells, then
these cancer cells could be eliminated by the body's own immune system. In order for
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the external tumor antigen to be presented in an MHC I, it must undergo crosspresentation.
Cross-presentation is the process of presenting an external antigen in an MHC I.
In order for this to occur, the antigen must be transported into the cytosol. This has
been shown to take place through two main types of pathways. In the vacuolar
pathway, antigens are brought into the cell by endocytosis in endosomes where they
are cleaved into smaller peptide fragments by proteases. These peptides can then be
loaded into a recycled MHC I present in the endosome. This complex traffics back to the
plasma membrane (Raghaven et al., 2008). The other pathways are known as TAPdependent. TAP (transporter associated with antigen processing) is found in the ER
membrane. In these TAP dependent pathways, antigens are endocytosed but
transported into the cytosol where they can be processed by proteosomes and
transported into the ER by TAP to be loaded into an MHC I (Raghavan et al., 2008).
To test for cross-presentation, antigens containing the peptide sequence
SIINFEKL were placed in the media of antigen presenting cells (splenocytes) in the
presence of cytotoxic T cells with T cell receptors (TCRs) specific to the SIINFEKL peptide
presented in an MHC I (B3Z cell line) and allowed to process the antigens. If these cells
were able to present the peptide SIINFEKL in their MHC I, by cross presenting the
antigen, the B3Z cells would be activated. The B3Z cells have been engineered so that
the activation of the TCR activates the LacZ gene, resulting in the production of
β-galactosidase (β-gal) (Kartunnen & Shastri, 1991).
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The antigens used in this assay were: ovalbumin (OVA), which naturally contains
the SIINFEKL sequence; EVI, which is composed of the external domain of the HER2
protein, the SIINFEKL sequence, and the internal domain of the HER2 protein;
EVIrGM, which is EVI conjugated to granulocyte macrophage colony-stimulating factor
(GM-CSF); and EA2-EVI, which is a variation of EVI with an altered external domain.
These four antigens were compared for their ability to be presented and activate
cytotoxic T cells. EVIrGM was shown to significantly activate the T cells compared to the
other antigens. It is predicted that the GM-CSF conjugated to the protein is able to bind
the GM-CSF receptor on antigen presenting cells and the antigen would be endocytosed
along with the receptor as it undergoes its normal recycling process.
After demonstrating that GM-CSF conjugated to EVI significantly increased crosspresentation, it was hypothesized that GM-CSF alone might increase cross-presentation
through increased endocytosis and therefore increase presentation of SIINFEKL.
Granulocyte macrophage colony-stimulating factor acts as a growth factor for
lymphocytes to promote growth and differentiation. Both OVA and EVI were tested for
their presentation in the presence of J558 supernatant. The J558 cell line produces
large amounts of GM-CSF.

Methods
RPMI method:
Splenocytes were isolated into complete RPMI media as described previously.
After incubating at 37 °C and 5% CO2 for 4-5 hours, the splenocytes were counted and
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resuspended into complete RPMI media. B3Z cells in complete RPMI media were also
counted and resuspended. The splenocytes and B3Z cells were added 1:1 to a 96 well
plate containing antigens serially diluted as described previously, starting with 10 μM of
antigen. The antigens used were OVA, EVI, EVIrGM, and EA2-EVI. Control wells
contained splenocytes, B3Z cells and PBS. Control wells did not contain antigen. The
plate was incubated 24 hrs at 37 °C and 5% CO₂, and then the amount of β-gal
production was determined using a GloRunner luminometer and the Luminescent β-gal
detection Kit II (Clontech).

Serial dilution of GM-CSF:
A 96 well plate was set up with the same concentration of antigen (OVA or
SIINFEKL) in each well, but a serial dilution of J558 supernatant, which acted as the
source of GM-CSF. Ovalbumin was added to each well at a concentration of 150 μM in
PBS. Twenty-five microliters of J558 supernatant was added to the first wells to start a
serial dilution as described previously. A separate plate was prepared with EVI in each
well at a concentration of 8 μM. One hundred microliters of J558 supernatant was
added to the first wells to start a serial dilution. Control wells contained either antigen
without J558 supernatant, 25 μL J558 supernatant without antigen, or PBS. Splenocytes
and B3Z cells were then added to each well to a 1:1 ratio, bringing the total volume to
200 μL. The plates were each incubated at 37 °C and 5% CO₂ for 24 hrs and β-gal
production was assayed using the Luminescent β-gal detection kit II (Clontech) and the
GloRunner luminometer.
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Supplementing with GM-CSF:
A 96 well plate was set up with a serial dilution of antigen and equal amount of
J558 supernatant. OVA and EVI dilutions were set up starting with 10 μM of each as the
highest concentration. One hundred microliters of J558 supernatant was added to each
well. The control wells contained J558 supernatant alone. Splenocytes and B3Z cells
were then added 1:1 to each well. The plate was incubated at 37 °C and 5% CO₂ for
24 hrs before the β-gal production was assayed using the Luminescent β-gal detection
kit II (Clontech) and the GloRunner luminometer.

Results:
Four different antigens were compared for their ability to activate the cytotoxic
T cell line, B3Z. The activation of the B3Z cells was determined by measuring the
amount of β-gal production. The β-gal produced by cells presented with each antigen
was compared to the β-gal produced by the controls using a student t-test (p < 0.05
significance). Since the same concentration of cells was not used for each assay, the
luminescent reading and antigen concentration are reported per 106 cells.
Three of the antigens showed significant β-gal production for at least two
concentrations of antigen. The EVIrGM showed a much larger activation than the other
antigens, but was significantly greater than the control at only the highest concentration
(Figure 1A). The next largest activation was by the EA2-EVI, which showed significant
β-gal production at all concentrations except the lowest (Figure 1A). OVA also showed
significant β-gal production at four of the lower concentrations, but did not activate the
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cells very much in comparison to the EVIrGM and EA2-EVI (Figure 1B). The HER2 antigen
containing the SIINFEKL sequence (EVI) did not have significant β-gal production at any
antigen concentration (Figure 1A & 1B).

Figure 1: B3Z Assay using
RPMI. Splenocytes and
B3Z cells were incubated
with serial dilution of
antigens for 24 hrs. The βgal production by the B3Z
cells as a result of
activation by the peptide
SIINFEKL presented in a
MHC I by the antigen
presenting cell was
measured by a
luminescent assay. The
antigens used were OVA,
EVI, EVIrGM, and EA2-EVI.
All antigens were at a
concentration of 10 μM
for the highest
concentration. Results are
reported per 106 cells,
since different
concentration of cells
were used for each
antigen. Luminescent
readings significantly
greater than PBS control
are indicated by the stars
(*), determined by a
student t-test (p < 0.05).
Panel A shows all antigens,
while panel B shows OVA
and EVI only.

A)

B)
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Since the EVIrGM gave the greatest β-gal production by B3Z cells in response to
the splenocytes presented with the highest antigen concentration, an assay was
conducted to test if the GM-CSF needed to be conjugated to the EVI, or if it would work
as a supplement in the media. The supernatant of J558 cells, collected previously, was
added to specific set concentrations of antigen to determine the concentration of
supernatant that would aid in activation of the cells by the antigen without activating
the cells on its own. Either 8 μM EVI or 150 μM OVA was added to each well of a plate
with different concentrations of J558 supernatant. The serial dilution of J558
supernatant was then compared to the antigen alone.
Both EVI and OVA showed significant β-gal production at the higher
concentrations of J558, with the 100 μL of J558 supernatant added to the EVI
responding the greatest (Figure 2). Different concentrations of cells were used for each
assay, so luminescence is reported per 106 cells. While the highest concentration of
J558 supernatant was able to significantly increase the activation of B3Z cells by EVI, it
did not by itself show a significant increase in β-gal production (data not shown). When
compared to cells with PBS instead of antigen, 100 μL of J558 without antigen did not
cause significant β-gal production.
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Figure 2: Optimal J558
dilution. Splenocytes and
B3Z cells were mixed with a
set concentration of
antigen (8 μM EVI or 150
μM OVA) and a serial
dilution of J558
supernatant. β-gal
production by the B3Z
cells, was measured by
luminescence per 106 cells.
Stars (*) indicate
significantly greater
luminescence than controls
(p < 0.05).

The 100 μL of J558 supernatant gave the highest response in combination with
EVI, and alone did not significantly activate the B3Z cells, so it was used as a supplement
with serial dilutions of antigen. OVA and EVI were added to splenocytes and B3Z cells in
serial dilutions, starting with 10 μM of each. One hundred microliters of J558
supernatant was then added to each concentration. Only one concentration of EVI and
two of the lower concentrations of OVA showed significant readings when compared to
cells with J558 supernatant and no antigen (Figure 3). While these readings were
significantly above control, the luminescence per 106 cells was much lower than the
EVIrGM itself (Figure 1A).
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Figure 3: B3Z Assay
with J558 supernatant.
Splenocytes and B3Z
cells were mixed with
serial dilutions of OVA
and EVI with 100 μL of
J558 supernatant per
well. Activation was
measured by
luminescent readings
significantly above the
control of cells with J558
supernatant alone, as
indicated by the stars (*)
(p < 0.05).

Discussion
In order for an external or recombinant antigen to have an effective cytotoxic
T cell response, the antigen must undergo cross-presentation into the MHC I pathway.
This process occurs in antigen presenting cells through two main pathways. The amount
of cross-presentation can be enhanced through alterations of the antigen itself and
targeting of receptors on the antigen presenting cell’s surface to encourage endocytosis
of the antigen. The antigens OVA, EVI, EVIrGM, and EA2-EVI were tested for their
efficiency of cross-presentation in the MHC I through activation of the cytotoxic T cell
line B3Z.
The antigen which caused the greatest response in B3Z cells as measured by the
most β-gal production and therefore the highest luminescent reading was the EVIrGM.
The elevated β-gal production by EVI conjugated to GM-CSF may occur because it is able
to bind to the GM-CSF receptor and be internalized with the receptor. This would aid in
42

internalizing the antigen, and therefore increase the probability of undergoing crosspresentation from the external environment into the MHC I. It was demonstrated that
the GM-CSF conjugated to the EVI was able to improve cross-presentation when
compared to the EVI alone.
While the highest concentrations of EVIrGM showed significant β-gal production,
the dose response curve was not quite as expected. Using a serial dilution of antigen, it
would be expected that the second highest luminescence would be half the
luminescence of the highest concentration, since the concentration of antigen was
reduced 50% with each dilution. This pattern was not observed for any of the antigens.
This suggests that none of the antigens were presented to their full potential. While
some appeared to undergo cross-presentation, none were able to give a response
correlated to the amount of antigen presented. The data points themselves also had a
large variation, making it hard to draw conclusions about the activation of the T cells by
the splenocytes.
In addition to EVIrGM, OVA and EA2-EVI also had a moderate increase in
luminescence compared to controls, with some antigen concentrations significantly
greater than the control. Ovalbumin acts as a positive control because it is a native
protein containing the SIINFEKL sequence. This shows that OVA is able to be processed
naturally by the antigen presenting cells and undergo cross-presentation to a certain
extent. The EA2-EVI was also able to undergo some cross-presentation, with an even
higher efficiency than the OVA itself. This could be due to the extracellular protein
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modification, which may have some ability to increase movement into the cell
cytoplasm independent of endocytosis.
Following the increased luminescence with EVIrGM, it was tested whether the
effect of GM-CSF was only seen when conjugated to EVI. When a serial dilution of J558
supernatant, containing large amounts of GM-CSF, was added to consistent amounts of
antigen, it appeared that the more supernatant that was added, the larger β-gal
production there was. This may indicate more antigen presentation, or improved crosspresentation, and is likely due to greater activity of the splenocytes. When the highest
concentration of J558 supernatant (GM-CSF source) was added to serial dilutions of
antigen however, no dose response was seen. This suggests that the GM-CSF may
increase cross-presentation when added as a supplement to the media, but is much
more effective at increasing cross-presentation of the antigen when conjugated to the
protein. The ability of GM-CSF to promote lymphocyte growth was not in itself enough
to increase presentation.
The EVI antigen alone was not able to be processed by the splenocytes for crosspresentation as seen in Figure 1. There was not a significant increase in β-gal
production at any concentration of EVI. This indicates that while variations of the EVI
protein were able to be presented by the antigen presenting cell and activated the
cytotoxic T cells, EVI alone was not. The EVI protein would therefore need to be
modified in order to make it a productive antigen for a vaccine. One possible method
may be to glycosylate the EVI in attempt to increase cross-presentation.
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CHAPTER 2: SUPER-ACTIVATION OF SPLENOCYTES

Introduction:
Anti-tumor immunity by antigens specific to the tumor type could be developed
to form an effective treatment. In order to optimize the outcome of such a treatment,
the tumor antigen would need to be efficiently presented in a high concentration to
elicit activation of as many T cells as possible. One way to increase presentation of an
antigen would be to have more MHC I molecules available in each cell for binding of
peptides produced from the tumor antigen. These peptides in the MHC I would then be
able to activate cytotoxic T cells specific to the antigen.
The ionophore ionomycin has been shown to increase the number of MHC I
molecules within antigen presenting cells by its ability to induce synthesis of several
cytokines. Ionomycin acts to increase calcium influx inside the cell, activates protein
kinase C (PKC) pathways, and induces the production of the cytokines IL-2
(Chatila et al., 1989) and interferon-γ (Jabrane-Ferrat et al., 1999). These cytokines are
involved with the inflammatory response. In order to increase MHC I production,
splenocytes were super-activated with ionomycin. Ionomycin was added to the media
and incubated for 48 hours along with the appropriate antigens, allowing for maximal
presentation.
Super-activation increases the presentation of antigen, but also increases the
length of time that presentation must occur. Hosken et al. (1989) showed that it takes
as little as 45-60 minutes for OVA peptides to be presented in the MHC I. While the
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protein is able to be processed by the antigen presenting cell, and presented on the cell
surface in a short amount of time, it is unknown how long the SIINFEKL/MHC I complex
will remain on the cell surface. In the super-activation assay the splenocytes are
allowed to process and present the antigen for 48 hrs. It is questionable whether the
peptide/MHC I remain on the cell surface for that long.
Ludewig et al. (2001) demonstrated that the antigen gp33 could be rapidly
presented in an MHC I and elicit a cytotoxic T cell response. However, the
peptide/MHC I complex presentation did not last very long. One day after presentation
of the antigen, a cytotoxic T cell response was no longer able to be activated, suggesting
the peptide/MHC I was no longer presented on the surface of the antigen presenting
cells (Ludewig et al., 2001). If this is the case for the OVA peptide, SIINFEKL, presented
in the MHC I, activation of the B3Z cells may not occur after the splenocytes have
incubated with the antigen for 48 hrs, even with the aid of the ionomycin superactivation. A time course of antigen presentation was conducted to determine if
antigen incubation time effected the activation of B3Z cells.

Methods:
B3Z assay super-activating splenocytes with ionomycin:
Splenocytes were isolated into serum free AIM-V media as described previously.
Splenocytes were incubated with ionomycin and serial dilution of antigen for 48 hours
at 37 °C and 5% CO₂ before adding the B3Z cells. The antigens used were OVA, EVI,
EVIrGM, and the peptide SIINFEKL. After incubating for an additional 24 hours, β-gal
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production was determined using the Luminescent β-gal detection kit II (Clontech) and
the GloRunner Luminometer. A serial dilution of β-gal was used as a standard. The
luminescence readings, which correspond to β-gal production, taken from the B3Z cells
could then be compared to the standard to calculate the amount of β-gal produced.
The same β-gal standard serial dilution was used for each plate so that luminescence
readings between plates could be compared.

Time course of antigen presentation:
Splenocytes were super-activated in AIM-V media as described previously, but
without antigen. After the 48 hour incubation, antigen at the same concentration was
added to each of six plates with splenocytes. The splenocytes were then incubated for
1, 2, 4, 8, 24 or 48 hrs with the same concentration of antigen at 37 °C and 5% CO₂
before adding B3Z cells. The antigens used were either 10 μM OVA or EVI. After adding
B3Z cells, the plates were incubated an additional 24 hrs before reading the
luminescence on the GloRunner luminometer.

Results:
Splenocytes were super-activated with ionomycin and antigen to determine if
antigen presentation could be increased. Ionomycin acts on the splenocytes to increase
cytokine production, leading to an increase in the number of MHC I produced by the
cell. With an increased amount of MHC I available, the antigen presenting cells may be
able to present more peptides and activate more cytotoxic T cells.
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Four different antigens were assayed for their ability to activate B3Z cells: OVA,
EVI, EVIrGM, and the peptide SIINFEKL. Only the SIINFEKL peptide showed significant
activation above the control consisting of cells treated with PBS and ionomycin
(Figure 4), but this was only at two of the lower concentrations. EVI and OVA did not
show significant β-gal production at any concentration of antigen. Even the EVIrGM,
which was able to significantly activate the B3Z cells using the RPMI method (Chapter 1)
was not able to produce significant β-gal production using the super-activating method.

Figure 4: B3Z Assay
Super-activating
splenocytes.
Splenocytes were
incubated with
ionomycin and serial
dilution of the
antigens OVA, EVI,
SIINFEKL and EVIrGM
for 48 hours. B3Z
cells were then
added for an
additional 24 hrs and
assay for activation
by luminescence.
The luminescence
was then compared
to a β-gal control to find the amount of β-gal produced. Stars (*) indicate significant β-gal
production compared to controls (p < 0.05).

Since an increased response was not observed with the super-activation of
splenocytes, a time course of antigen presentation was conducted to determine the
stability of the presented peptides in the MHC I. The splenocytes were super-activated
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with ionomycin for 48 hours before adding the antigen. The splenocytes were then
incubated with the antigen for a given amount of time to allow for presentation.
B3Z cells were then added to the splenocytes to become activated by any SIINFEKL that
was able to be presented by the splenocytes.
Both OVA and SIINFEKL were assayed for antigen presentation over time. The
controls of PBS or PBS and ionomycin were also assayed at each time point. The
antigens were allowed to incubate with the splenocytes for 1, 2, 4, 8, 24, or 48 hrs
before adding the B3Z cells. The time allowed for antigen presentation did not appear
to affect the activation of the B3Z cells. At no time point was there significant β-gal
production by either antigen above the base lines of PBS and PBS with ionomycin
(Figure 5).

Figure 5: Time course of
Antigen Presenation.
Splenocytes were superacivated with ionomycin for
48 hrs before adding
antigens. The antigens OVA
and SIINFEKL incubated with
the splenocytes for the
indicated amount of time
before adding B3Z cells and
incubating for an additional
24 hrs to allow for
activation. The activation of
B3Z cells is reported as the
amount of β-gal produced.
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Discussion:
In an attempt to increase antigen presentation, splenocytes were superactivated with ionomycin, which acts to increase calcium influx and activate cytokine
release. The super-activation however did not increase the presentation of any of the
four antigens assayed. The only antigen with β-gal production significantly above the
PBS plus ionomycin control was SIINFEKL. This only occurred at two of the lower
concentrations. The antigen EVIrGM, which was able to elicit the most β-gal production
using the RPMI method, was not able to produce a significant amount of β-gal.
This raised the concern of how long the peptide will stay presented on the cell
surface, since the antigens were incubated with the splenocytes for 48 hrs before the
B3Z cells were added. If the peptide/MHC I was not able to stay presented a substantial
period of time, the splenocytes would not be able to activate the B3Z cells, as was
observed. Hosken et al. (1989) showed that presentation of OVA peptides took as little
as 45-60 minutes to be presented on an antigen presenting cells surface. Ludewig et al.
(2001) demonstrated that while a specific antigen was able to be presented quickly in
the MHC I and induce a cytotoxic T cell response, the presented peptides lasted for less
than one day.
To investigate this issue, a time course of antigen presentation was done.
Splenocytes were first super-activated with ionomycin and incubated with antigen for
set amounts of time before adding the B3Z cells. There was no difference in B3Z cell
activation for any of the time points. The β-gal production was never significantly
greater than that of the PBS or PBS plus ionomycin controls. This suggests that either
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the splenocytes are not able to present the SIINFEKL peptide at all, or the B3Z cells are
not responding to the presentation. Even when the peptide SIINFEKL itself was
presented to antigen presenting cells, the B3Z cells were not activated. While OVA
would have to be processed by the cell into the SIINFEKL peptide, it should be much
easier for the cell to present the peptide, since it should not need to be processed. This
however did not appear to be the case.
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CHAPTER 3: ASSAYS FOR B3Z FUNCTIONALITY

Introduction:
The results of the previous experiments have suggested that the B3Z cells are
unresponsive to peptides presented in the MHC I of murine splenocytes. This could be a
result of the splenocytes being unable to process and present the antigens. However,
not even the SIINFEKL peptide was able to induce β-gal production by the B3Z cells.
Instead, it was hypothesized that the B3Z cells were not able to be activated. In order to
determine the functionality of the B3Z cells, several assays tested for T cell receptor
(TCR) presence and activity, as well as the presence of the LacZ gene.
To determine if the B3Z cells were able to produce β-gal, they were stimulated
with a combination of Phorbol 12-Myristate 13-Acetate (PMA) and ionomycin. The B3Z
cells are constructed so that the LacZ gene, which codes for β-gal, is under the control of
the nuclear factor of activated T cells (NF-AT) element of the IL-2 gene. When the T cell
receptor (TCR) gets activated by binding the specific MHC/peptide, the receptor sends a
signal through calcium dependent pathways including protein kinase C (PKC) and
calmodulin to activate NF-AT, which then stimulates the transcription of IL-2. Since
β-gal is under control of the IL-2 enhancer, it will also get transcribed upon TCR
activation (Karttunen & Shastri, 1991). The PMA and ionomycin are able to enter the
cells and simulate TCR activity. The combination of the two has shown to increase
calcium influx and activate PKC and calcium-calmodulin pathways (Chatila et al., 1989).
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They have also been shown to directly activate β-gal production in B3Z cells
(Kartunnen & Shastri, 1991).
If the B3Z cells were able to produce β-gal, the next step would be to look for
TCR activation. In order to assay this, splenocytes were fixed with glutaraldehyde to
prevent protein processing. When cells are fixed, the SIINFEKL peptide is still able to be
presented by MHC I molecules already on the surface of the antigen presenting cells.
Hosken et al., (1989) showed that OVA peptides could be presented on the cell surface
without internalization. These peptide/MHC I complexes were then able activate a
cytotoxic T lymphocyte response (Hosken et al., 1989). By mixing the splenocytes with
SIINFEKL and fixing the cells, SIINFEKL should be presented in the MHC I on the surface
of the cells and should be able to activate the TCR on B3Z cells. Therefore if the TCR is
functional, it should cause β-gal production.
In another attempt to increase antigen presentation, and therefore activate the
TCR of B3Z cells, splenocytes were super-activated with a much larger concentration of
ionomycin. Ionomycin is able to cause production of the cytokines IL-2
(Chatila et al., 1898) and interferon-γ (Jabrane-Ferrat et al., 1999). The supplementary
effect of ionmycin is to increase the number of MHC I molecules by increasing the
production of interferon-γ. Interferon-γ has specifically been shown to up-regulate the
transcription of the class I MHC heavy chain (Schroder et al., 2004). For this reason,
splenocytes were also super-activated specifically with interferon-γ.
In addition to up-regulating the MHC I, interferon-γ has been shown to increase
the number of N-extended peptides formed by proteosomes in the cytosol. The
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N-extension binds to a receptor on the ER membrane, allowing it to be transported into
the ER. Once in the ER, the N-extension is cleaved off and the peptide is available to be
combined with an MHC I (Rock et al., 2004). Not only does interferon-γ increase the
number of peptides transported into the ER by N-extension, but it has also been shown
to specifically increase the number of SIINFEKL peptides produced from the processing
of ovalbumin. In the presence of interferon-γ, proteosomes form immunoproteosomes
which are able to increase the number of intact SIINFEKL peptides from 6% in normal
proteosomes to 11% (Rock et al., 2004).
Finally, in order to assay for the presence of the TCR on the B3Z cells surface, an
immunofluorescence assay was conducted. Using new B3Z cells obtained from the
University of California Berkeley, courtesy of Dr. Shastri, the TCR of the new B3Z cells
were then compared to the TCR of B3Z cells used for all previous experiments. The
“old” B3Z cells had been in culture for over a year. A decreased presence of the TCR
could explain the lack of activation of the B3Z cells by the splenocytes presented with
antigens containing the SIINFEKL peptide.

Methods:
Activating B3Z cells with PMA/ionomycin:
B3Z cells were activated with PMA and ionomycin as described previously. A
serial dilution of PMA and ionomycin was added to B3Z cells. After a 4 hour incubation,
the β-gal production by the B3Z cells was measured by luminescence using the
Luminescent β-gal detection kit II (Clontech) and the GloRunner Luminometer. The
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assay was conducted with B3Z cells grown in IMDM, cells grown in RPMI, and cells that
were grown in RPMI but then had the media switched to IMDM.

Fixing splenocytes:
Splenocytes were isolated into AIM-V media as described previously. Antigens
were then added to the splenocytes and incubated for 15 min. Half of the cells for each
antigen type were fixed using glutaraldehyde. The cells were incubated for an
additional hour before adding B3Z cells. The B3Z cells were incubated with the
splenocytes for 4 hrs before determining the β-gal production using the Luminescent βgal detection kit II (Clontech) and the GloRunner Luminometer.

Super-activating splenocytes with increased ionomycin concentration:
Splenocytes were isolated into AIM-V media as described previously. Serial
dilutions of the antigens were added to the splenocytes with 5 μM ionomycin. Other
wells containing a serial dilution of OVA were treated with 70 μM ionomycin. Controls
were PBS, PBS plus 5 μM ionomycin, and PBS plus 70 μM ionomycin. After superactivating for 48 hrs, B3Z cells were added. After an additional 24 hr incubation, the
β-gal production was determined using the Luminescent β-gal detection kit II (Clontech)
and the GloRunner luminometer.
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Super-activating splenocytes with interferon-γ:
Splenocytes were again isolated into AIM-V media as described previously.
Antigens were plated at a constant concentration and a serial dilution of interferon-γ,
starting with 200 μM interferon-γ. SIINFEKL and OVA were both used at 10 μM. A 200
μM interferon-γ control alone was used. The splenocytes were incubated for 48 hrs
before adding B3Z cells and incubating an additional 24 hrs. The β-gal production was
then determined using the Luminescent β-gal detection kit II (Clontech) and the
GloRunner luminometer.

Immunofluorescence of TCR on B3Z cells:
To assay for the presence of the T cell receptor (TCR) on the surface of the B3Z
cells, an immunofluorescence assay was conducted. The primary antibody was a mouse
antibody specific to the TCR. The secondary antibody was specific to mouse IgG and
conjugated to biotin. Streptavidin-FITC was then used to detect the biotin. The FITC
fluoresced green under the fluorescent microscope. The cells were stained with DAPI to
visualize their nucleus, which fluoresced blue. New B3Z cells, obtained from the
University of California Berkeley were compared to the B3Z cells used previously that
had been in culture for over a year for the presence of the TCR.

Results:
To assay if the B3Z cells were still capable of producing β-gal, the cells were
stimulated with a combination of PMA and ionomycin. Cells grown in the two types of
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media used in the previous experiments, RPMI or IMDM, were compared. Cells grown
in RPMI but switched to IMDM media two days prior were also assayed. The cells were
able to produce β-gal as demonstrated by the large luminescence measured (Figure 6).
All points were significantly greater than the PBS control. The PMA or ionomycin when
added individually did not activate β-gal production (data not shown); only the
combination of the two was able to stimulate β-gal production. The IMDM had a greater
luminescence compared to the cells grown in RPMI, indicating more β-gal production.

Figure 6: PMA and
Ionomycin activation of
B3Z cells. B3Z cells grown
in two different types of
media were incubated
with serial dilutions of
PMA and ionomycin. The
β-gal production was
measured by
luminescence. All points
were significantly
(p < 0.05) greater than the
luminescence of the B3Z
cells treated with only PBS.
Ionomycin and PMA when
added individually were
not able to stimulate B-gal
production (data not shown).

Splenocytes were then presented with either SIINFEKL or OVA and fixed with
glutaraldehyde to prevent the cell from processing the antigen. The SIINFEKL should be
able to combine with MHC I molecules on the splenocyte surface and subsequently
activate the B3Z cells, if the B3Z cells have a functioning TCR. The fixed splenocytes
were able to significantly activate B3Z cells at some antigen concentrations using both
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the OVA and SIINFEKL compared to the control of splenocytes that were fixed without
antigen (Figure 7). The cells presented with OVA that were not fixed also had some
activation significantly greater than the control cells not fixed but treated with PBS. The
cells presented with SIINFEKL did not.

Figure 7: Fixing
Splenocytes with
Glutaraldehyde.
Splenocytes were
incubated with antigen
for 15 min before fixing
with glutaraldehyde.
B3Z cells were added
one hour later and
allowed to incubate for
24 hrs. Significant
(p < 0.05) luminescence
above the PBS control
or fixed cells with PBS
control is indicated by
the stars (*).

When splenocytes were super-activated with a large amount of ionomycin
(70 μM), the cells were able to activate B3Z cells to produce β-gal, but in an antigen
independent manner. When SIINFEKL and OVA were presented to the splenocytes and
super-activated with 5 μM ionomycin as before, there was no significant β-gal
production above the PBS plus ionomycin control (labeled as PBS + ionomycin in
Figure 8). The OVA plus 70 μM ionomycin stimulated significant β-gal production
compared to the 5 μM ionomycin and OVA. However the β-gal produciton was
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significantly less than the 70 μM ionomycin plus PBS. It was therefore concluded that
the 70 μM ionomycin was itself causing the activation rather than the OVA (Figure 8).

Figure 8: Super-activating
splenocytes with increased
ionomycin. Splenocytes
were super-activated with
14 times the ionomycin as
used in previous superactivations. The antigens
were all added to 10 μM
and compared to PBS alone.
The stars (*) indicate
luminescence significantly
above the control of PBS
alone and 5 μM ionomycin
(p < 0.05).

To avoid the antigen independent activation of the B3Z cells, splenocytes were
super-activated with interferon-γ, which still increases the number of MHC I molecules
on the antigen presenting cells. The splenocytes were incubated with a constant
concentration of antigen but a serial dilution of interferon-γ to determine what
concentration would have the optimal effect for super-activation. The super-activation
with interferon-γ did not have any effect on the ability of the splenocytes to activate the
B3Z cells. There was only one concentration of SIINFEKL with significant β-gal
production compared to the controls, while the remaining concentrations of
interferon-γ did not differ from the controls (Figure 9).
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Figure 9: Super-activating
splenocytes with
Interferon-γ. Splenocytes
were super-activated with
decreasing concentrations
of interferon-γ and set
concentration of antigen to
determine the optimal
amount of interferon-γ to
super-activate splenocytes.
The antigens OVA and EVI
were at a concentration of
10 μM. Luminescence was
then compared to the PBS
control. Stars (*) indicated
significant readings above
the control (p < 0.05).

An immunofluorescence study of the B3Z cells was conducted to test for the
presence of the TCR. New B3Z cells were obtained from UC Berkeley, and compared to
the B3Z cells that had been used in all previous experiments and had been in culture for
over a year. The TCR was detected using an antibody conjugated to FITC which
fluoresced green. The cells were stained with DAPI which fluoresced blue. As can be
seen in Figure 10, the new B3Z cells had a much higher density of green staining,
indicating an increased number of TCR compared to the old B3Z cells.
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A)

B)

Figure 10: Immunofluorescence of B3Z cells. The TCR of B3Z cells was detected using a mouse
antibody specific to the TCR. The secondary antibody was specific to mouse Ig and conjugated
to biotin. The biotin was then fluoresced green using streptavidin-FITC. The cells were stained
with DAPI and fluoresced blue. Both pictures are magnified at 40X on a fluorescent microscope.
(A) shows the old cells. (B) shows the new cells from UC Berkeley.

Discussion:
Previous experiments during this project had suggested that the B3Z cells used
were not able to be adequately activated. To determine if the B3Z cells were still
capable of producing β-gal, they were activated with ionomycin and PMA. The
ionomycin and PMA act together to increase calcium signaling, leading to the
transcription of the LacZ gene of the B3Z cell. The B3Z cells were able to make
β-gal, and did so in correlation to the amount of ionomycin and PMA added. This result
indicates the LacZ gene is intact and functional. The B3Z cells grown in IMDM media
showed a greater luminescence and better correlation to PMA and ionomycin
concentration compared to those grown in RPMI.
Since the B3Z cells were able to transcribe and produce β-galactosidase, it was
next assayed whether the TCR was able to recognize SIINFEKL in the MHC I. This was
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determined without the splenocytes having to process the antigens by presenting the
SIINFEKL to the splenocytes and then fixing them with glutaraldehyde. The SIINFEKL can
bind to empty MHC I molecules on the surface of the antigen presenting cell. If the TCR
of the B3Z cells are functional, the B3Z cell should be activated by the fixed splenocytes.
Some concentrations of SIINFEKL and OVA were able to stimulate β-gal
production in B3Z cells exposed to the fixed splenocytes that was greater than the β-gal
production of the B3Z cells exposed to the fixed splenocytes without antigen control.
However, there was no correlation between the amount of antigen presented and the
amount of β-gal produced. OVA should not be able to bind to MHC I on the outside of
the splenocyte because only peptides 8-12 amino acids long can fit in the MHC I
complex (Hosken et al., 1989). OVA would need to be processed by the cell in order to
produce the necessary peptides, and therefore served as a negative control. The
observation that OVA was able to give readings significantly above control and at about
the same value as the SIINFEKL that gave significant readings, suggests that B3Z cells
were not actually being activated by the antigen in the MHC I.
Presentation of OVA by splenocytes that were not fixed also gave significant
readings above the PBS control. While the readings were statistically significant, it was
interesting to note that they did not differ from the OVA readings obtained from the
fixed cells. The unfixed cells presented with SIINFEKL did not significantly stimulate βgal production. It could be assumed that the fixed cells, while able to bind and present
the SIINFEKL peptide in MHC I molecules present on the cell surface, would not be
expected to present a significant amount of antigen when compared to cells that were
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not fixed and allowed to process the antigen. These results support the conclusion that
the “old” B3Z cells are not responding to the peptide presented in the MHC I.
In an attempt to get the splenocytes to present more antigen peptides and
therefore possibly activate the B3Z cells, splenocytes were super-activated with a large
(70 μM) concentration of ionomycin. While the lower concentration (5 μM) of
ionomycin was not able to cause β-gal production in cells presented with OVA, the
higher concentration (70 μM) did. When this higher concentration of ionomycin was
added to cells with PBS instead of antigen however, an even larger response was seen.
This demonstrated that it was the ionomycin, and not the OVA, that was activating the
B3Z cells.
The ionomycin must have been activating the splenocytes, which then were able
to activate the B3Z cells, since the ionomycin itself was washed off before the B3Z cells
were added when the media was changed from AIM-V to IMDM. The activation of the
B3Z cells was in an antigen independent manner, since the OVA did not cause an
increased response when mixed with the high concentration of ionomycin compared to
the high concentration of ionomycin alone.
In order to avoid the T cell activation by ionomycin affecting the splenocytes, but
still be able to get the favorable effect of enhanced MHC I production by the
splenocytes, interferon-γ was used to super-activate the cells. Not only should it
increase the number of MHCs, but it has been shown to increase the amount of intact
SIINFEKL peptides produced by the proteosomes. However, when interferon-γ was
added at differing concentrations to the splenocytes, it had no effect on the β-gal
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production by the B3Z cells. We concluded this could be attributed to the lack of a
functioning TCR.
To assay if the TCR was still present on the surface of the B3Z cells, an
immunofluorescence assay was done. At this time new B3Z cells had been obtained
from UC Berkeley. The number of TCRs present on the new B3Z cells could then be
compared to the B3Z cells that had been used for the previous experiments. When the
cells were stained with antibodies specific to the TCR and then detected with FITC, there
appeared to be a much larger number of receptors on the new cells compared to the
old. It appeared that the old cells had lost some of their TCRs, and this may explain the
low levels of activation by SIINFEKL presented in the MHC I of splenocytes. The previous
assays were then repeated using the new cells with the larger number of TCRs.
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CHAPTER 4: ENZYME-LINKED IMMUNOSORBANT ASSAY OF SPLENOCYTES

Introduction:
The goal of this project was to increase the cross-presentation of the tumor
antigen HER2 by antigen presenting cells. In order to measure the amount of crosspresentation, a modified version of the HER2 protein containing the SIINFEKL peptide
was used. When presented by antigen presenting cells, it should activate the B3Z cell
line specific to the SIINFEKL peptide presented in the MHC I. Activation of the B3Z cells
had not been observed through the presentation of SIINFEKL from any of the antigens
presented to the splenocytes, or by the SIINFEKL peptide itself. In attempt to measure
the peptide presentation without using the B3Z cells, an enzyme linked immunosorbant
assay (ELISA) was conducted. This would provide a way to quantify antigen presentation
without relying on the activation B3Z cells.

Methods:
Splenocytes were isolated into serum free AIM-V media as described previously
and super-activated with antigen and 5 μM ionomycin for 48 hrs. OVA, EVI and SIINFEKL
were all used in serial dilutions. The splenocytes were assayed by ELISA as described
previously. Briefly, the splenocytes were fixed with formaldehyde and the wells were
blocked with goat serum. The antibody 25-D1.16 conjugated to biotin was incubated
with the cells for one hour. The antibody 25-D1.16 is specific to SIINFEKL presented in
the MHC I. The avidin-horse radish peroxidase (HRP) conjugated molecule was added
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and incubated an additional hour. The HRP was detected using an ELISA specific HRP
chemiluminescent detection kit (Pierce). Controls consisted of splenocytes with PBS
instead of antigen, splenocytes in media without anything added, and wells without
cells that were fixed, blocked and washed the same as the wells with cells.

Results:
The ELISA of SIINFEKL in the MHC I using splenocytes was meant to provide a
method of measuring antigen presentation without using the B3Z cells. The amount of
SIINFEKL presented in the MHC I was not able to be detected above the luminescence of
the PBS plus ionomycin control. None of the antigens (OVA, SIINFEKL, or EVI) stimulated
significant luminescence above the cells only control (Figure 10). The presentation of
SIINFEKL in the MHC I could not be detected using the antibodies and HRP luminescent
kit.

Figure 11: ELISA of SIINEKL
in the MHC I. Splenocytes
were super-activated with
ionomycin and a serial
dilution of antigen.
SIINFEKL/MHC I complexes
were then detected using a
biotin conjugated antibody.
Avidin-HRP was used to
detect the biotin. HRP was
detected using a
chemiluminescent kit.
Luminescence readings were
not significantly greater than
controls with PBS and
ionomycin for any
concentration of antigen.
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When the highest antigen concentration for each antigen was compared to the
cells only control or to empty wells that were treated the same, it was observed that the
cells alone and the empty wells gave the largest luminescent readings. Both were
significantly greater than the PBS plus ionomycin control (Figure 12).

Figure 12: Comparing
Controls of splenocyte
ELISA. The highest
concentration of each
antigen in Figure 11 is
shown compared to the
controls and empty
wells. The stars (*)
indicate luminescent
readings significantly
above that of the cells
with PBS and ionomycin
(p < 0.05).

Discussion:
In order to detect antigen presentation without using the cytotoxic T cell line
B3Z, an ELISA for SIINFEKL was conducted. An antibody specific to the peptide SIINFEKL
presented in the MHC I was used to determine the amount of antigen presentation from
serial dilutions of the antigens OVA, EVI and SIINFEKL. No significant presentation could
be detected using this method. While the EVI gave some large luminescent readings at
the smaller concentrations, they were not significantly greater than the PBS control.
The OVA and SIINFEKL gave no readings greater than the PBS control.
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This suggests that either the SIINFEKL peptide is not being presented by the
splenocytes, or this method was not an accurate way to detect antigen presentation. If
there was a lot of non-specific binding by the antibody or the avidin molecule, a
significant reading of SIINFEKL presentation may not be detectable. This seemed to be
the case, since the luminescent readings of cells alone or the wells that were processed
the same as the wells with cells gave luminescent readings significantly above the PBS
control. The wells that were blocked with goat serum, washed, and incubated with the
antibody and avidin in the same process as the wells with splenocytes showed the
highest luminescence of all the wells. They were significantly greater than the PBS with
splenocytes control. This suggests that there may be non-specific binding to the wells
that was not corrected by blocking with the goat serum.
Considering the cells in media alone, with no PBS or ionomycin added, resulted
in a luminescent reading that was significantly higher than PBS or PBS plus ionomycin
controls suggests there was non-specific binding by either the antibody or the avidin. If
this is the case, the ELISA, in our hands, does not seem to be an accurate measure of
antigen presentation. The new B3Z cells from UC Berkeley were next tested for their
ability to be activated by splenocytes, since it was demonstrated that they have more
TCRs than the old B3Z cells used in previous experiments (Chapter 3).
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CHAPTER 5: ASSAYS USING NEW B3Z CELLS

Introduction
After demonstrating that the B3Z cells received from UC Berkeley contained
more TCRs than the previously used B3Z cells (Chapter 3), the B3Z assays were repeated
using the new cells (hereafter referred to as new B3Z cells). With more TCRs available,
the activation of the B3Z cells should be assayable if the SIINFEKL peptide is presented
by the splenocytes. The presentation of the antigens was assayed using the RPMI and
both of the super-activation methods to find which method gave the greatest activation
of B3Z cells as determined by β-gal production. The cells were also fixed with
glutaraldehyde to determine if the SIINFEKL peptide was entering the cell and
undergoing the presentation process, or just binding to MHC I molecules on the outside
of the antigen presenting cells.

Methods
B3Z assay in RPMI
A B3Z assay was set up using the RPMI method described previously. Fifty
microliters of splenocytes at a concentration of 2.6x106 cells/mL and B3Z cells at
1.4x106 cells/mL in complete RPMI were mixed with serial dilutions of the antigens
SIINFEKL, OVA and EVI starting with 10 μM. The control was splenocytes and B3Z cells
with PBS (no antigen). The plate was incubated for 24 hrs at 37 °C and 5% CO₂ before
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determining the β-gal production using the Luminescent β-gal Detection kit II (Clontech)
and a Modulus microplate reader (Turner Biosystems).

Super-activating Splenocytes with ionomycin
A B3Z assay was set up to super-activate 100 μL of splenocytes at a
concentration of 1.3x106 cell/mL for 48 hrs in AIM-V media with 5 μM ionomycin and a
serial dilution of antigen as described previously. The dilutions were started with 10 μM
SIINFEKL, OVA or EVI. Controls were cells treated with PBS alone or PBS plus ionomycin.
The media was switched to IMDM and 100 μL of B3Z cells at a concentration of 7.0x10 5
cell/mL were added. The plate was incubated for an additional 24 hrs before
determining the β-gal production using the Luminescent β-gal Detection Kit II (Clontech)
and the Modulus microplate reader.

Super-activating splenocytes with interferon-γ
Splenocytes were super-activated as described previously in AIM-V media with
either 10 μM SIINFEKL or OVA and a serial dilution of interferon-γ, starting with 200 μM.
A serial dilution of interferon-γ without antigen was used to determine if the
interferon-γ itself was causing activation at each concentration. After 48 hrs, B3Z cells
in IMDM were added and the plate was incubated for 24 hrs more. The β-gal
production was then measured using the Luminescent β-gal Detection Kit II (Clontech)
and a Modulus microplate reader.
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Fixing splenocytes with glutaraldehyde
Splenocytes were incubated with antigen for 15 min. and then fixed with
glutaraldehyde as described previously. The antigens were SIINFEKL and OVA serially
diluted starting with 10 μM. The cells were then incubated for one hour before adding
the B3Z cells and incubating an additional 24 hrs. The β-gal production was then
measured using the Luminescent β-gal Detection Kit II (Clontech) and a Modulus
microplate reader.

Results:
The new B3Z cells were first assayed using the RPMI method. Splenocytes and
B3Z cells were mixed together with serial dilutions of antigen and incubated for 24 hrs.
The SIINFEKL caused β-gal production greater than the PBS control (Figure 13). Not only
did it cause significant β-gal production at every concentration of SIINFEKL, but it was
also correlated to the amount of antigen presented. The OVA and EVI however did not
give significant β-gal production compared to the control.
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Figure 13: B3Z assay using
RPMI method, new B3Z
cells. Splenocytes and B3Z
cells were mixed with serial
dilutions of SIINFEKL, OVA or
EVI and incubated for 24 hrs.
The β-gal production was
then measured as a
luminescent reading. All of
the SIINFEKL readings were
all significantly above the
control of PBS, as indicated
by the stars (*), while the
OVA and EVI were not
significant (p < 0.05).

The splenocytes were then super-activated with ionomycin to determine if the
presentation of SIINFEKL from the EVI and OVA proteins could be elicited, or if the β-gal
production from the antigen SIINFEKL could be increased. The SIINFEKL again produced
significant β-gal production by the B3Z cells when compared to the control of PBS and
ionomycin (Figure 14). The OVA and EVI however did not cause significant β-gal
production (Figure 14).
When the SIINFEKL β-gal production by the super-activation method was
compared to the RPMI method, it had significantly more β-gal production at all
concentrations except for the 5 μM (Figure 15). A β-gal standard was used to calculate
the amount of β-gal produced by the cells in each case. The luminescent values
between the two assays could then be compared. While the super-activation method
was not able to increase the β-gal production by EVI or OVA presentation, it caused
significant increase in the presentation of the SIINFEKL peptide compared to the RPMI
method.
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Figure 14: Super-activating
splenocytes with
ionomycin. Splenocytes
were incubated with a serial
dilution of the antigens
SIINFEKL, OVA or EVI and 5
μM ionomycin for 48 hrs
before adding B3Z cells. The
β-gal production was then
measured by luminescence.
The SIINFEKL readings were
significantly
(p < 0.05) greater than the
control of PBS and
ionomycin.

Figure 15: Comparison of
SIINFEL presenation by
the RPMI method to
super-activation. The βgal produced by SIINFEKL
presentation using the
RPMI method is shown
compared to the the βgal produced when
SIINFEKL was presented
with super-activation of
the splenocytes. The
super-activation method
gave significantly higher
β-gal production than the
RPMI method, as
indicated by the stars
(*)(p <0.05).

The splenocytes were super-activated with interferon-γ as done previously. A
serial dilution of interferon-γ with either 10 μM SIINFEKL or OVA at each concentration
of interferon-γ. The SIINFEKL showed significantly higher β-gal production when
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compared to the PBS control (Figure 16). The interferon-γ dilution itself, without
antigen, was significantly higher than the PBS control at one concentration. When
SIINFEKL was compared to the interferon-γ at each concentration, SIINFEKL was
significantly higher than the interferon-γ alone. The OVA in combination with
interferon-γ did not have any significant β-gal production compared to the PBS control.

Figure 16: Superactivating splenocytes
with interferon-γ.
Splenocytes were
activated with a set
amount of antigen,
either 10 μM SIINFEKL or
OVA, and a serial
dilution of interferon-γ
for 48 hrs. The B-gal
produced was then
compared to the PBS
control. (A) SIINFEKL
produced significantly
more β-gal than the PBS
control. The SIINFEKL +
interferon-γ was also
compared to the
interferon-γ alone at
each concentration for
β-gal production and
was found to be
significantly greater
(p < 0.05) as indicated by
the stars (*). (B) The
interferon-γ dilution
without antigen did not
differ from the PBS
control except at
6.25 μM as indicated by
the star.

A)

B)
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Since the SIINFEKL was presented to the splenocytes using all three antigen
presentation methods at 10 μM, the β-gal production as a result of 10 μM SIINFEKL
presentation was compared between the three methods (Figure 17). The comparison of
all three methods showed they were significantly different in their β-gal production
(p < 0.05). The super-activation with ionomycin gave the most production, while the
interferon-γ super-activation gave the least.

Figure 17: Comparing the
three methods of antigen
presentation. The β-gal
production as a result of
presentation of 10 μM
SIINFEKL to splenocytes was
calculated for each
presentation method. The
RPMI method produced
significantly more β-gal than
the Interferon-γ method and
the ionomycin method
produced significantly more
β-gal than the RPMI method.
Bars with different letters
are significantly different
(p < 0.05).

To assay if the splenocytes were processing the antigen, or if the SIINFEKL
peptide was able to bind to MHC I on the outside of the cell, the splenocytes were fixed
with glutaraldehyde. The splenocytes were presented with SIINFEKL or OVA for
15 min and then half of the splenocytes were fixed. The β-gal production of the B3Z
cells mixed with the fixed splenocytes was compared to the fixed PBS control, while the
non-fixed cells were compared to the PBS control with non-fixed cells.
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The fixed cells that were presented with SIINFEKL did not cause significant β-gal
production by the B3Z cells compared to the fixed control cells, with one exception
(Figure 18B). The cells presented with SIINFEKL that were not fixed caused significantly
greater β-gal production at all concentrations when compared to the non-fixed PBS
control. When compared to the fixed cells presented with SIINFEKL, the non-fixed
SIINFEKL presented cells also produced significantly greater β-gal at all concentrations of
SIINFEKL (Figure 18A).
The fixed cells presented with OVA did not have significant β-gal production
when compared to the control cells that were fixed and presented with PBS. The nonfixed, OVA presented cells did not differ from the PBS control except at two low
concentrations (Figure 18B).
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Figure 18: Effect of Fixing
Splenocytes with
Glutaraldehyde.
Splenocytes were
presented with serial
dilution of the antigens
SIINFEKL or OVA for 15
min before fixing half the
cells with gludaraldehyde.
The cells were incubated
for another hour before
B3Z cells were added and
then incubated an
additional 24 hrs. (A) The
SIINFEKL fixed was
compared to the SIINFEKL
presented to non-fixed
cells and was found to be
significantly lower at all
concentrations. Fixed and
non-fixed OVA did not
differ. (B)The fixed cells
treated with antigen were
compared to fixed cells
with PBS.
Non-fixed cells were
compared to non-fixed
cells with PBS. Significant
differences are indicated
by stars (*) (p < 0.05).

A)

B)B)

Discussion:
The new B3Z cells received from UC Berkeley were assayed for their ability to be
activated by the presentation of SIINFEKL from the antigens EVI, OVA and the peptide
SIINFEKL itself. Since the new B3Z cells had been shown to have a larger number of
TCRs than the old cells, they should be able to recognize antigen presented by the
antigen presenting cells more robustly. The new B3Z cells were able to produce
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significant β-gal production when the splenocytes were presented with SIINFEKL peptide
using any of the three activation methods. In all three cases the response to SIINFEKL
corresponded to the SIINFEKL concentration. This demonstrated that the B3Z cells were
responding to a difference in presentation of the SIINFEKL peptide by becoming more
activated with an increase in antigen concentration and therefore an increase in antigen
presentation.
The SIINFEKL was able to cause significantly more activation when presented
using the super-activation with ionomycin method then with the RPMI method. It is
suspected that the increased MHC I production due to ionomycin’s effects on the
antigen presenting cells caused more presentation of the peptide. The B3Z cells were
also able to respond to a difference in presentation of the SIINFEKL peptide by varying
the concentrations of interferon-γ. The higher the concentration of interferon-γ used,
the more SIINFEKL peptide was presented and therefore more activation of B3Z cells
was observed through β-gal production and detected by luminescence.
While all three methods showed significant β-gal production when the cells were
presented with SIINFEKL, the super-activation with ionomycin caused the most β-gal
production. Since all three assays were done with 10 μM SIINFEKL, the β-gal production
resulting from presentation of 10 μM SIINFEKL was compared between each method.
The super-activation with ionomycin gave the largest production of β-gal, with the next
largest from the RPMI method, and the smallest from the super-activation with
interferon-γ. Even though interferon-γ has the advantage of making the antigen
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presenting cells produce more MHC I molecules, the added effect of other pathways
activated by ionomycin must also aid in increasing the presentation of SIINFEKL.
While the SIINFEKL peptide was able to be presented by the antigen presenting
cells, the EVI and OVA proteins did not seem to be processed by APCs into the necessary
SIINFEKL peptide for presentation by the splenocytes. The EVI and OVA did not give
significant luminescent readings compared to controls using either the RPMI or the
super-activating methods. While super-activating the splenocytes allowed for more
SIINFEKL presentation, neither the EVI nor the OVA responded appropriately. This is an
important observation when considering the optimal composition of a tumor vaccine. It
suggests that a specific peptide ready to be directly combined with an MHC I would be
able to mount a larger T cell response than a whole protein that needs to be processed
by the cell. It implies that the most efficient and effective vaccine to elicit a cytotoxic T
cell response is a specific antigenic peptide. A more detailed study on the peptides
formed when HER2 is cleaved by proteosomes in the cell and which of these peptides
are most efficiently cross-presented by antigen presenting cells resulting in the
activation of cytotoxic T cells may lead to a new agent for vaccine formation.
To determine if the antigen presenting cells were actually internalizing the
SIINFEKL peptide and cross-presenting it to the surface of the cell in an MHC I, the
splenocytes were presented with SIINFEKL and OVA but then fixed to prevent the cells
from further processing the antigen. If the SIINFEKL was simply combining with MHC I
molecules already on the surface of the cell, then fixing the splenocytes should not
affect the β-gal production from the B3Z cells in response to the presented SIINFEKL.
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When the cells were fixed, the SIINFEKL presentation was significantly lower than when
the cells were not fixed. This demonstrated that cross-presentation was occurring.
One concentration of SIINFEKL in the cells that were fixed was able to cause
significant production of β-gal when compared to the control of the fixed cells
presented with PBS. This suggests that it is possible for the SIINFEKL to combine with
MHC I already on the surface of the splenocytes as described by Hosken et al. (1989). As
expected, the OVA did not cause significant β-gal production when the splenocytes were
fixed. The OVA protein is too large to fit in the MHC I already on the cell surface and
therefore needs to be processed by the cell, so it should not be able to cause β-gal
production when the cells are fixed, as observed.
Since the SIINFEKL was able to cause activation of the new B3Z cells as detected
by β-gal production, it shows that the model is able to detect cross-presentation despite
the negative outcomes of previous experiments. Because this was the case, the EVI
protein was next conjugated to mannan to assay the original hypothesis that
glycosylation would increase cross-presentation.
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CHAPTER 6: GLYCOSYLATION OF EVI AND SIINFEKL

Introduction
Glycosylation of proteins has been demonstrated to not only increase antigen
presentation (Tan et al., 1997), but also increase cross-presentation of the antigen
(Apostolopoulos et al., 1995) through interaction with the mannose receptor
(Burgdorf et al., 2007). In an attempt to increase the cross-presentation of the tumor
antigen HER2, the EVI variation of HER2 was glycosylated by conjugation to oxidized
mannan according to Apostolopoulos et al. (1995). It was then assayed for its ability to
be presented in the MHC I and cause activation of the cytotoxic B3Z cells. Since the new
B3Z cells had been demonstrated to be activated by SIINFEKL presented in the MHC I, an
increase in the presentation of EVI through glycosylation should be observable. Given
that the SIINFEKL peptide was the only antigen to be detected by the B3Z cells in this
study, it was also glycosylated through conjugation to oxidized mannan to determine if
its presentation would be improved.

Methods
Conjugating Mannan to antigens
Oxidized mannan (Sigma) was conjugated to EVI or SIINFEKL according to
Apostolopoulos et al. (1995) as described previously. Mannan was oxidized by sodium
periodate and eluted through a HiTrap Q Sepharose HP column (GE Healthcare)
equilibrated with sodium biocarbonate buffer (pH 9.0) to elute only the oxidized
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mannan. The oxidized mannan was then incubated with antigen overnight at room
temperature. The resulting glycosylated protein was assayed for the degree of
glycosylation.

Assays for glycosylation of antigens
The glycosylated proteins were assayed for glycosylation by electrophoresis and
using a glycoprotein detection kit (Pierce). The proteins were first assayed using
electrophoresis as described previously to determine if the glycosylated antigen
migrated at a different rate compared to the non-glycosylated antigen due to the added
molecular weight of the conjugated mannose.
A glycoprotein carbohydrate estimation kit (Pierce) was used to determine the
amount of glycosylation of the proteins. To test for carbohydrate content, 50 μL of
standards and samples were added to a 96 well plate. Controls were glycoprotein
detection reagent, oxidized mannan and PBS. Twenty-five microliters of 10 mM sodium
meta-periodate (prepared just prior to use) was added to each well and mixed for
30 seconds on a plate shaker. After incubating for 10 min at room temp, 150 μL of
glycoprotein detection reagent (prepared just prior to use) was added to each well and
mixed for 30 seconds. The plate was incubated at room temp for one hour before
measuring absorbance at 560 nm using the Modulus Microplate Reader.
The absorbance of the standards was then compared to the absorbance of the
samples and controls. A standard curve was produced by subtracting the absorbance for
the blank (glycoprotein detection reagent control) from the absorbance of the protein
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standards. The absorbance of the protein standards with the blank subtracted was then
plotted with carbohydrate content (%) based on the values provided by the
manufacturer. The plot was fit for a linear regression and the resulting equation was
used to calculate the carbohydrate content of the samples. If the absorbance of the
sample was above 5.00, the carbohydrate content could not be calculated since the
exact absorbance was too high to be read on the microplate reader.
In addition, the amount of protein in both the glycosylated and nonglycosylated samples was quantified using the Qubit Flurometer as described previously
to determine the concentration of protein in the solutions.

B3Z assay using RPMI
The glycosylated EVI and SIINFEKL were then assayed for cross-presentation by
activation of B3Z cells using the RPMI method as described previously. The glycosylated
and non-glycosylated antigens were mixed with splenocytes and B3Z cells and incubated
for 24 hrs. The controls were oxidized mannan, diluted oxidized mannan (at the same
dilution as the glycosylated SIINFEKL, 1:60) and PBS. The β-gal production was then
determined using the Luminescent β-gal detection kit II (Clontech) and the Modulus
Microplate Reader.

Results
The antigens EVI and SIINFEKL were conjugated to oxidized mannan as described
by Apostolopoulos et al. (1995). To determine if the proteins were glycosylated, a gel
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electrophoresis was conducted on the glycosylated proteins and the non-glycosylated
proteins. When the electrophoresis was performed, the bands for the glycosylated EVI
were not visible on the gel (Figure 19A). The lanes containing the glycosylated EVI had
a dark stained area where the protein was loaded into the well. It was hypothesized
that the glycosylated EVI was too large to enter the gel. The bands in the lanes with
glycosylated SIINFEKL did appear to shift slightly compared to the non-glycosylated
SIINFEKL. The bands are very faint, but when looking at the leading edge of the
glycosylated band compared to the leading edge of the band for the non-glycosylated
SIINFEKL, it did not migrate as far down the gel, (Figure 19 B).

B)

A)

Figure 19: Electrophoresis of Glycosylated Antigens. The glycosylated proteins were
electrophoresed on a Tris-Glycine gel along with the non-glycosylated version of the protein to
determine if glycosylation had occurred. Panel A depicts the gel with EVI. From left to right,
lane 1 is the molecular weight standard Mark 12 (Invitrogen). Lanes 2 and 4 are the glycosylated
EVI at 5 and 15 μL respectively. Lanes 3 and 5 are the non-glycosylated EVI at 5 and 15 μL
respectively, with the EVI protein appearing as the darkest band closest to the wells. Lane 6 is
the molecular weight standard See Blue (Invitrogen). Panel B shows the gel with SIINFEKL. The
lanes were set up as described for the EVI but with glycosylated and non-glycosylated SIINFEKL.
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EVI and SIINFEKL were both tested for glycosylation using the Glycoprotein
Carbohydrate Estimation Kit (Pierce). The non-glycosylated EVI and SIINFEKL were also
tested for carbohydrate content. A standard curve was prepared from a set of standard
glycoproteins (Figure 21). The linear regression for the standard curve was found to be:
Absorbance = 0.2512 (% Carbohydrate) + 0.5857
Using this formula, the carbohydrate content of the EVI and SIINFEKL were calculated.
The EVI (non-glycosylated) was found to be 1.3% glycosylated, while the EVI conjugated
to mannan could not be calculated because the absorbance was over 5.00 and the
absorbance could not be determined by the microplate reader. The SIINFEKL was
estimated to be 0% glycosylated, since its absorbance was only off by 0.01 from the
blank, was while the SIINFEKL conjugated to mannan could not be calculated because
the absorbance was over 5.00 (Table 1).
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Table 1: Estimation of carbohydrate content of sample proteins. The carbohydrate content of
non-glycosylated EVI and SIINFEKL and glycosylated EVI and SIINFEKL was found using a
glycoprotein estimation kit. The absorbance of the samples was found at 560nm. The blank of
glycoprotein detection reagent was subtracted from each absorbance and this value was used to
compare the sample to the absorbance of standard glycoproteins with known carbohydrate
content which also had the blank subtracted from them. Samples with an absorbance over 5.00
could not be estimated since the exact absorbance could not be detected by the microplate
reader.

Samples
Blank
EVI
EVI
Glycosylated EVI
Glycosylated EVI
Glycosylated SIINFEKL
Glycosylated SIINFEKL
SIINFEKL
Mannan
Mannan

Protein
(mg/mL)
0
2.5
0.25
0.45
0.045
0.45
0.045
2.5
0
diluted
1:10

Estimated
Absorbance Absorbance Carbohydrate
(560 nm)
– Blank
Content (%)
3.92
0
0
4.82
0.91
1.3
3.61
-0.30
5.00
1.08
5.00
1.08
5.00
1.08
5.00
1.08
3.93
0.01
0
5.00
1.08
5.00

1.08

-

Figure 20: Glycoprotein
Standard Curve. A
glycoprotein standard
curve was found using the
glycoprotein standards
Lysozyme, Bovine Serum
Albumin, Ovalbumin, ApoTransferrin, Fetuin, and
α1–Acid Glycoprotein and
the glycoprotein detection
reagent. Samples were
mixed with sodium metaperiodate and detection
reagent. The absorbance
at 560 nm was then
measured.
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It was uncertain whether the glycoprotein detection reagent was detecting
glycosylated protein or just the mannan still in solution. Since the protein bands for the
glycosylated EVI did not appear on the gel electrophoresis, the protein content of the
glycosylated EVI and SIINFEKL was measured using the Qubit flurometer (Invitrogen) to
determine the protein concentration. The glycosylated EVI was found to be 199.4
μg/mL, while the non-glycosylated EVI at the same dilution was 390 μg/mL. The
glycosylated SIINFEKL was found to be 196.2 μg/mL, while the non-glycosylated SIINFEKL
at the same dilution was found to be 250 μg/mL.
Finally, the glycosylated and non-glycosylated proteins were assayed for
presentation by splenocytes using the RPMI method. Both the glycosylated and nonglycosylated SIINFEKL resulted in significant β-gal production compared to the controls
of diluted mannan and PBS respectively. The glycosylated SIINFEKL approached a
significant difference at the highest concentration compared to non-glycosylated
SIINFEKL (p = 0.078). The glycosylated EVI also showed significantly greater β-gal
production when compared to the oxidized mannan control and the non-glycosylated
EVI at each concentration. The non-glycosylated EVI did not have significant β-gal
production above the PBS control (Figure 22). The glycosylated EVI also had significantly
greater β-gal production than the glycosylated SIINFEKL and non-glycosylated SIINFEKL
at concentrations of 3.93, 1.96, 0.98 and 0.49 μM.
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Figure 21: B3Z Assay
with Glycosylated
Antigens. A B3Z
assay was conducted
using the RPMI
method with
glycosytlated
SIINFEKL and EVI
compared to nonglycosylated SIINFEKL
and EVI. Significance
is indicated by stars
(*) (p < 0.05). All
glycosylated EVI
readings are also
significantly greater
than the nonglycosylated EVI.

Discussion
The antigens EVI and SIINFEKL were conjugated to oxidized mannan, as
described by Apostolopoulos et al. (1995), in attempt to increase their crosspresentation. To test if the antigens were glycosylated, the proteins were separated by
electrophoresis. Both glycosylated and non-glycosylated versions of EVI and SIINFEKL
were assayed. If the proteins were glycosylated, the protein band should not migrate as
far on the gel due to the added size of the conjugated mannan.
A band in the lane loaded with glycosylated EVI was not evident on the gel.
There was however a dark area in the well of the lane loaded with 15 μL of glycosylated
EVI, suggesting that the EVI protein may have been glycosylated and was too large to
enter the gel. The glycosylated SIINFEKL bands were very faint compared to the non88

glycosylated SIINFEKL, but the leading edge of the glycosylated band appeared to have
migrated slightly less compared to the leading edge of the non-glycosylated band. It
was difficult to tell if this was a significant difference, as the non-glycosylated SIINFEKL
bands were very wide, presumably due to the large concentration of SIINFEKL in the
sample.
Since the electrophoresis did not irrefutably confirm glycosylation, a
glycoprotein estimation kit was used to determine the carbohydrate content of the
proteins. Both glycosylated and non-glycosylated EVI and SIINFEKL were assayed for
carbohydrate content, along with the control of oxidized mannan. According to the
standard curve formed from glycoprotein standards, EVI that was not conjugated to
mannan had slight glycosylation. The SIINFEKL was estimated to not be glycosylated,
since its absorbance was only 0.01 more than the blank.
The oxidized mannan control also gave an absorbance over 5.00, indicating the
estimation kit was not identifying glycoproteins as a whole, but instead corresponded to
the carbohydrates in solution. For this reason, the carbohydrate content attached to
the EVI and SIINFEKL could not be estimated. The mannan in solution could be causing
the large absorbance rather than mannan conjugated to the proteins.
To assay if the proteins were still in solution or to determine if they had been
degraded in the conjugation process, since the bands had not appeared or were very
faint on the electrophoresis gels, the concentration of protein for each antigen solution
was found using the Qubit flurometer. The glycosylated EVI and SIINFEKL solutions had
concentrations of 199.4 μg/mL and 196.2 μg/mL respectively. The non-glycosylated EVI
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and SIINFEKL were assayed to be 390 μg/mL and 250 μg/mL respectively. Each solution
should have had a concentration of 450 μg/mL as this was what the non-glycosylated
proteins were diluted to prior to the assay. The glycosylated proteins were also diluted
to this concentration when mixed with the oxidized mannan to undergo glycosylation.
This indicated that there was a slight loss of protein through the glycosylation
procedure. This could explain the faintness of the SIINFEKL bands on the gel. This also
reinforces the hypothesis that EVI is glycosylated, since there is still protein present in
solution, but the band did not appear on the gel. This was most likely due to the
glycosylated EVI being too large to enter the gel.
With moderate certainty that the EVI and SIINFEKL were glycosylated by the
mannan conjugation procedure, they were assayed for their ability to be crosspresented and activate the B3Z cell line using the RPMI method. The glycosylated
SIINFEKL showed similar β-gal production compared to the non-glycosylated SIINFEKL,
until the highest concentration of antigen. At the highest concentration, the
glycosylated SIINFEKL approached a significantly greater β-gal production compared to
the non-glycosylated SIINFEKL (p = 0.078).
The EVI showed a significant difference in β-gal production at all concentrations
when glycosylated compared to the non-glycosylated. It was also the first time, during
this study, that EVI showed a significant increase in β-gal production compared to the
control. The glycosylation appeared to increase the cross-presentation of the EVI,
thereby increasing the number of B3Z cells that were activated and the amount of β-gal
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produced. This supported the hypothesis that glycosylation of the HER2 protein EVI
would increase cross-presentation.
Cross-presentation of EVI was achieved through glycosylation, and the amount
of β-gal produced by B3Z cells in response was even greater than both the glycosylated
and non-glycosylated SIINFEKL peptide at four concentrations. This suggests that
through glycosylation, an antigen can be processed by the cell and presented more
efficiently than the peptide alone. When considering a glycosylated antigen as a vaccine
vector, it would have not only the advantage of increasing presentation of a specific
antigenic peptide, but also allow for presentation of other peptides within the whole
protein. It would be hypothesized that since glycosylation was able to increase the
presentation of SIINFEKL, it would also increase the presentation of other peptides
formed from the processing of the HER2 protein.
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CHAPTER 7: PROTEIN TRANSFECTION AGENTS

Introduction
The goal of this project was to increase cross-presentation of the tumor antigen
HER2. To accomplish this, the protein needs to be delivered from the extracellular
environment into endosomes or the cytosol so that it enters into a MHC I presentation
pathway. Since antigens presented in the MHC I come from within the cytosol, HER2
antigen delivered directly into the cytosol by a transfection agent should increase the
cross-presenation.
For this reason, several different protein transfection agents were assayed for
their ability to increase the cross-presentation of the HER2 protein EVI. The protein
transfection agents are designed to bind to proteins and chaperone them across the cell
membrane, into the cell. Once inside the cell, the transfection agents release the intact,
still functional protein. If the protein transfection agents deliver the protein across the
membrane, it would be more likely for the protein to be processed as an internal
antigen and therefore be presented in the MHC I.
The protein transfection agents assayed for their ability to increase crosspresentation were TransPass-P (New England Biolabs), jetPRIME PEI
(Polyplus-transfection) and PULSin (Polyplus-transfection). All of these agents have
been demonstrated to successfully transfect living cells with minimal toxicity, according
to the manufacturers. The TransPass-P protein transfection agent forms a non-covalent
bond with the protein to deliver the protein into mammalian cells by endocytosis. The
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non-covalent association prevents protein degradation within the endosome when
endocytosed (New England Biolabs).
The jetPRIME (PEI) is a transfection agent intended for DNA transfection, but was
assayed for its ability to bind and transfect protein. Polyethyleneimine (PEI) is a
synthetic branched polymer that has a high cationic charge density. The cationic PEI
forms noncovalent interactions with DNA, and promotes cellular uptake by endocytosis
(Grezelinski et al., 2006). PEI has been also shown to bind and deliver proteins into
living cells in vitro and in vivo. When the PEI binds to the protein, the protein becomes
cationized and adheres to the cell surface through an ionic charge interaction. The
PEI/protein complex is internalized by the cells without binding to a receptor or
transporter (Futami et al., 2005). Since PEI has been used as a protein transfection
agent, the jetPRIME was assayed for its transfection ability with the EVI protein.
The third transfection agent used was PULSin (Polyplus-transfection). PULSin is
an amphiphile cationic molecule that also forms non-covalent bonds with the protein. It
binds to anionic cell-adhesion receptors on the cell surface, which are then internalized.
Once in the cell, the complexes of PULSin/protein are released into the cytoplasm and
disassemble (Polyplus-transfection). If PULSin is able to deliver the EVI protein directly
into the cytoplasm, it should get processed as an internal antigen and be presented in
an MHC I, thereby achieving cross-presentation.
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Methods
TransPass-P protein transfection agent
Splenocytes were isolated as described previously into serum free AIM-V media.
The antigens were mixed with the transfection agent TransPass-P (New England
BioLabs) as described by the manufacturer. Each antigen was diluted to 10 μM and
mixed with the TransPass-P for 20 min at room temp. The resulting transfection mix was
added to the splenocytes and incubated at 37 °C and 5% CO₂ for 4 hrs. B3Z cells were
added to the plate in IMDM media as described for the super-activating splenocytes
procedure. The plate was incubated for an additional 24 hrs at 37 °C and 5% CO₂ before
determining the β-gal production using the Luminescent β-gal Detection Kit II (Clontech)
and the Modulus Microplate Reader.

jetPRIME transfection agent:
Splenocytes were isolated into complete RPMI media as described previously.
Each antigen was diluted to a concentration of 1 μg/mL in PBS. To make the
transfection mixes, 2 μL of diluted antigen, 4 μL jetPRIME (Poly Plus Transfection) and
100 μL jetPRIME buffer were mixed together and incubated at room temperature for
10 min. The transfection mix was added to the splenocytes and incubated overnight at
37 °C and 5% CO₂. B3Z cells in complete RPMI were added to the plate and incubated
an additional 24 hrs at 37 °C and 5% CO₂ before determining the
β-gal production using the Luminescent β-gal Detection Kit II (Clontech) and the
Modulus Microplate Reader.
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PULSin protein transfection agent
Splenocytes were isolated into complete RPMI as described previously. Before
adding the cells to the plate, they were washed with complete serum free RPMI to
remove serum. Each antigen was diluted to a concentration of 1 μg/mL in PBS.
To make the transfection mixes, 2 μL of antigen diluted to 1 μg/mL, 4 μL PULSin
transfection agent (Poly Plus Transfection) and 100 μL 20mM HEPES buffer were mixed
together and incubated at room temperature for 15 min. Transfection mix was added
to the splenocytes and incubated overnight at 37 °C and 5% CO₂. B3Z cells in complete
RPMI media were added to the plate and incubated for 24 hours at 37 °C and 5% CO₂
before determining the β-gal production using the Luminescent β-gal Detection Kit II
(Clontech) and the Modulus Microplate Reader.

Cell Viability Assays
Splenocytes and B3Z cells were assayed for viability in the presence of each
protein transfection agent and the buffer used to make the transfection mix, if
applicable. Wells with media alone and cells alone were used as controls. The cells
were added to the plate in the same media and incubated for the same period of time
as described for each transfection agent. The cell viability was then assayed using the
Cell Titer Glo Luminescent Assay (Promega) and the Modulus Microplate Reader. The
reagent measures cell viability by ATP production.
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Results
The first protein transfection agent applied in attempt to deliver the antigens
into the splenocytes for presentation as an internal antigen was TransPass-P (New
England Biolabs). When SIINFEKL was presented with TransPass-P or alone, the β-gal
production was greater than the TransPass-P or PBS controls. In the presence of
TransPass-P however the SIINFEKL had a significantly small β-gal production when
compared to SIINFEKL without TransPass-P (Figure 22A). The TransPass-P did not have a
significant effect on OVA presentation, as neither the OVA with TransPass-P or OVA
alone were significantly above the controls. It appeared that the β-gal produced by OVA
presentation was lower when presented with TransPass-P, though not statistically
different (Figure 22B).
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Figure 22: B3Z Assay
using the Protein
Transfection Agent
TransPass-P.
Splenocytes were
incubated with
TransPass-P protein
transfection agent
and antigen for 4
hours before adding
B3Z cells. The β-gal
production was then
measured as a
luminescent reading.
Readings significantly
(p < 0.05) greater
than the PBS control
or the TransPass-P
without antigen
control are indicated
by the stars (*). The
SIINFEKL and SIINFEKL
+ TransPass-P differed
significantly. Panel A
shows all antigens
while panel B shows
only OVA.

A)

B)

A cell viability assay to determine the amount of ATP present was also conducted
to determine if the TranPass-P had an effect on cell proliferation. There was no
significant difference in the cell viability of splenocytes and B3Z cells when mixed with
TranPass-P compared to cells that were not (Figure 23).
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Figure 23: Viability of
cells with TransPass-P.
Cell Viability of
splenocytes and B3Z cells
in the presence of
TransPass-P was
measured by ATP
production through a cell
titer glo luminescent
assay. There was no
significant difference (p <
0.05) between cells in
the presence or absence
of TransPass-P.

The jetPRIME (PEI) transfection agent (Polyplus-transfection) was next assayed
for its ability to transfect the antigens SIINFEKL, OVA and EVI. The SIINFEKL peptide
gave signifcant β-gal production above the jetPRIME buffer control and the jetPRIME
with jetPRIME buffer control when combined with jetPRIME or SIINFEKL alone. In
combination with the jetPRIME, the β-gal production was significantly lower than the
SIINFEKL presented in jetPRIME buffer alone (Figure 24A). When presented with the
jetPRIME buffer, OVA and EVI both were able to stimulate β-gal production significantly
greater than the control of jetPRIME buffer. In combination with jetPRIME transfection
agent, OVA and EVI did not stimulate significant β-gal production greater than the
jetPRIME control. For EVI, not only was the β-gal production not significant, but the
β-gal production was less than the control (Figure 24B).
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Figure 24: PEI as a
protein transfection
agent. The PEI
transfection agent
jetPRIME was incubated
with splenocytes and
antigen overnight before
adding B3Z cells. The βgal production was then
measured as a
luminescent reading.
Readings significantly (p
< 0.05) above the
jetPRIME buffer control
or the jetPRIME control
without antigen are
indicated by the stars
(*). The luminescence
from β-gal production in
cells presented with
each antigen was also
significantly higher than
antigen with jetPRIME.
Panel A shows all
antigens. Panel B shows
only OVA and EVI.

A)

B)

A cell viability assay was also conducted on the cells with jetPRIME to determine
if it had any cell cytotoxicity that would account for the decrease in β-gal production by
B3Z cells in the presence of jetPRIME compared to control. While the cells with PEI
(jetPRIME) did not vary significantly from the cells alone, the cells with jetPRIME buffer
had significantly more luminescence than the either the cells alone or the cells with
jetPRIME (Figure 25).
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Figure 25: Cell
viability in the
presence of PEI. Cell
viability of splenocytes
and B3Z cells in the
presence of jetPRIME
(PEI) was measured by
ATP production using a
luminescent assay.
There was no
significant difference
(p < 0.05) between
cells in the presences
of PEI and control cells.
The cells in the
presence of jetPRIME
buffer were
significantly different from the control cells and cells with jetPRIME as indicated by the star (*).

The protein transfection agent PULSin (Polyplus-transfection) was assayed for its
ability to transport the proteins into the cytoplasm of the antigen presenting cells and
therefore increase cross-presentation of the antigens. When SIINFEKL was presented
with PULSin or alone it gave β-gal production above the PULSin control or PULISin buffer
without antigen. In the presence of PULSin, the β-gal production was significantly lower
than SIINFEKL presented without PULSin. The OVA with PULSin stimulated production
of significant amounts of β-gal compared to PULSin alone, but the OVA with only the
PULSin buffer was not significantly higher than the control of PULSin buffer. The β-gal
production in response to OVA in the presence of PULSin was also significantly higher
than OVA alone (Figure 26).
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The EVI with PULSin or EVI alone (with PULSin buffer) did not stimulate a
significant β-gal production above the PULSin control or PULSin buffer control
respectively. The EVI alone resulted in significantly higher B-gal production than EVI
with PULSin, which resulted in β-gal production lower than its control (Figure 26).

Figure 26: PULSin as a
protein transfection
agent. The protein
transfection agent
PULSin was incubated
with splenocytes and
antigen overnight
before adding B3Z cells.
The β-gal production
was then measured as a
luminescent reading.
Significant readings
compared to the
controls (buffer or
PULSin without antigen)
are indicated by the
stars (*)(p < 0.05). The
luminescence from β-gal
production in cells
presented with SIINFEKL
or EVI was significantly
higher than SIINFEKL or
EVI with jetPRIME. The
β-gal produced by cells
with OVA and PULSin
was significantly higher
than OVA alone. Panel A
shows all antigens while
panel B shows only OVA
and EVI.

A)

B)
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When the cell viability assay was conducted on splenocytes and B3Z cells in the
presence of the PULSin protein transfection agent or the buffer, the cells incubated with
PULSin were not significantly different from the cells alone. Luminescence resulting
from ATP production in cells with PULSin buffer however was significantly greater than
both the cells with PULSin and the cells alone (Figure 27).

Figure 27: Cell viability in the
presence of PULSin. Cell
Viability of splenocytes and
B3Z cells in the presence of
PULSin was measured by ATP
production through a
luminescent assay. There was
no significant difference
between cells in the presence
of PULSin and control cells.
The cells in the presence of
PULSin buffer were
significantly different from
the control cells and cells with
PULSin as indicated by the
star (*)(p < 0.05).

Discussion
Several different transfection agents were assayed for their ability to increase
the cross-presenation of the antigens SIINFEKL, EVI and OVA. The transfection agents
form noncovalent interactions with the proteins and help to transport them across the
cell membrane. Once the protein is inside the cell, it was hypothesized that it would be
processed as an internal antigen and presented in the MHC I. If this was achieved by the
protein transfection agents, presentation of the antigens in the presence of the
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transfection agent should increase the amount of β-gal produced by the B3Z cells as a
result of activation of the B3Z cells from presentation of the peptide SIINFEKL in the
MHC I of the splenocytes.
The protein transfection agent TransPass-P caused a decrease in β-gal
production when the antigens were presented with this agent. The SIINFEKL was able to
be presented and caused a significantly higher luminescence as a result of β-gal
production compared to the controls of TransPass-P or PBS alone. The TransPass-P
significantly decreased the β-gal production compared to SIINFEKL alone. This appeared
to be the case for OVA as well, even though the difference was not statistically
significant. The TransPass-P was did not increase cross-presentation, but instead
seemed to inhibit cross-presentation. This difference was not due to toxicity of the
cells, as the cells with TransPass-P gave a similar luminescence in the cell viability assay
compared to the cells alone.
The transfection agent jetPRIME, a variation of PEI, had similar results. The
jetPRIME significantly reduced the amount of β-gal produced as a result of SIINFEKL
presentation when compared to SIINFEKL alone, even though both values were again
significantly above the controls. This decrease cannot be attributed to toxicity, as the
cells alone and with jetPRIME were not significantly different in the cell viability assay.
The EVI and OVA stimulated β-gal production significantly above the controls
when presented alone. Presentation of EVI and OVA with PEI significantly reduces β-gal
production. Interestingly, the jetPRIME buffer combined with the antigens (but not
jetPRIME) stimulated β-gal production in the B3Z cells. Additionally, increased cell
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viability occurred when the cells were incubated with jetPRIME buffer compared to
jetPRIME or no treatment. However, this difference is accounted for when the cells
with buffer alone control is subtracted from the luminescent reading of the cells with
antigen and buffer.
As with the other transfection agents, PULSin caused a significant decrease in
β-gal production when mixed with SIINFEKL compared to SIINFEKL alone. The SIINFEKL
presentation was still significantly greater than the controls in both cases. The EVI
showed a similar pattern in that it caused more β-gal production alone than in
conjunction with the PULSin. As with the jetPRIME, this may be attributable to the fact
that the cells with buffer alone had increased cell viability compared to cells alone or
with PULSin. The decrease is not a result of toxicity of the PULSin, as the cells with
PULSin were not significantly different from the cells alone during the cell viability assay.
The OVA in combination with PULSin was the only antigen/protein transfection
agent combination that displayed significant β-gal production when compared to the
antigen alone. The OVA and PULSin also stimulated a significantly greater luminescence
reading, from β-gal production, when compared to the PULSin alone control. This
suggests that the PULSin was able to bind and transport OVA into the cell, increasing the
amount of cross-presentation.
In most cases the transfection agents significantly decreased presentation of the
antigens, as observed by a decrease in β-gal production when in combination with the
transfection agent. This decrease could be a result of the transfection agent binding,
but not releasing the antigen once in the cell, or it could also be caused by the antigen
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getting endocytosed to get into the cell, but then entering the MHC II pathway, since
most extracellular antigens that are endocytosed get presented in the MHC II. Instead
of increasing cross-presentation, the transfection agents may have been simply
increasing MHC II presentation, which is not detected with this assay.
The OVA increase in cross-presentation however demonstrates that it is possible
to use protein transfection agents to increase cross-presentation. As shown by the
decrease in EVI presentation when using the same transfection agent, it implies that the
right transfection agent for each antigen must be found. Since proteins are very
different from one another, compared to DNA or RNA which have the consistent
backbone structure, it would be important to find a transfection agent that is able to
bind the protein based on its unique amino acid composition. Not only must it be able
to bind the protein, but it also must be able to release it once it gets into the cell. A
more serious study of the characteristics of HER2 or other antigens and the properties
of various transfection agents may lead to the discovery of agents that are able to
increase cross-presentation as was observed with OVA.
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SYNOPSIS AND CONCLUSIONS

HER2 overexpression in breast cancer leads to a very aggressive form of the
disease. It has been correlated with decreased survival and faster progression when
compared to breast cancers not overexpressing HER2. For this reason, HER2 has proven
to be an excellent target for treatment, as the cancer cells not only depend on HER2 for
survival, but HER2 has also the been shown to be the initial cause of transforming
normal cells into cancer (Moasser, 2007a). Its presence has also been correlated to a
population of cancer stem cells, which impel tumorgenesis (Korkaya et al., 2008). By
targeting HER2 in treatments, the driving force of the cancer can be eliminated,
effectively preventing the growth of cells overexpressing the receptor.
The first treatment to take advantage of this concept was the monoclonal
antibody trastuzumab. Although the development of trastuzumab has led to a longer
onset of disease progression and lower death rate at one year (Slamon et al., 2001), a
relatively large fraction of patients still relapse and one-third of the patients with
advanced forms of the disease fail to respond to the treatment (Korkaya et al., 2008).
This along with the severe side effect of cardiac dysfunction in 4.7% of patients treated
with trastuzumab (Eisenhauer, 2001) encourages the development of a novel treatment
for targeting HER2 in breast cancer.
A treatment option that has recently been explored is the formation of a vaccine
against HER2. Evidence has shown that HER2 could be a possible candidate for a
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vaccine, despite it being a self-protein. Patients with HER2 overexpressing tumors have
a pre-existing, though low magnitude, immune response to HER2
(Bernhard et al., 2002). A vaccine to boost this pre-existing immunity or elicit a novel
immunity against HER2 could be the next step at developing a more effective treatment
for HER2 positive breast cancer.
The optimal immune response to a tumor vaccine is the activation of cytotoxic T
cells. These cells are specific to antigens on the surface of cells and target them for
destruction. Cytotoxic T cells have demonstrated to be required for tumor rejection by
the immune system (Rohrback et al., 2005). In order for a vaccine to activate cytotoxic T
cells, the antigens composing the vaccine need to be presented in a MHC I. This
requires the antigen to be cross-presented from the extracellular environment to the
internal antigen processing pathway.
The goal of this project was to optimize the cross-presentation of the tumor
protein HER2. Glycosylation has shown to increase antigen presentation in general
(Tan et al., 1997), as well as to specifically increase the amount of cross-presentation to
elicit a cytotoxic T cell response (Apostolopoulos et al., 1995). To determine if this was
true for HER2, a variation of the HER2 protein, EVI, was conjugated to oxidized mannan.
The glycosylated EVI demonstrated an increased cytotoxic T cell response when
glycosylated compared to non-glycosylated as measured by the activation of the
cytotoxic T cell line B3Z through production of β-gal. Glycosylated EVI caused
significantly greater β-gal production compared to non-glycosylated EVI. This data
supports previous studies demonstrating that glycosylation of a protein increased cross107

presentation. Evidence from this study, as well as from others, indicates that
glycosylated HER2 antigens should be considered as a viable construct for an effective
tumor vaccine.
The glycosylated EVI was able to cause significant β-gal production, even when
compared to the β-gal produced by the glycosylated and non-glycosylated SIINFEKL
peptides at four concentrations. This demonstrated that through glycosylation, an
antigen can be presented more efficiently than the peptide alone, increasing the
number of cytotoxic T cells activated in response to that antigen. A glycosylated antigen
as a vaccine vector, would have not only the advantage of increasing presentation of a
specific antigenic peptide, as demonstrated with SIINFEKL presentation, but also allow
for other peptides within the whole protein to be processed and presented. It could be
hypothesized that since glycosylation was able to increase the presentation of SIINFEKL,
it would also increase the presentation of other peptides formed from the processing of
the HER2 protein.
The B3Z cells are specifically activated by the SIINFEKL peptide presented in the
MHC I. In order for EVI and OVA to cause β-gal production, they needed to be cleaved
into fragments and the SIINFEKL peptide presented in the MHC I to elicit B3Z cell
activation. Since the SIINFEKL peptide produced more β-gal at the same concentrations
of antigen as the proteins, it illustrated that the peptide was more efficiently in to
causing activation then the whole proteins, except when the EVI was glycosylated. This
demonstrates that peptides capable of direct presention in the MHC I, without being
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cleaved by proteosomes or digestive enzymes within the lysosome, can be efficiently
presented and elicit a strong response by cytotoxic T cells.
Data from this study indicates that while the peptide is ready to be presented in
an MHC I, it still needs to be internalized by the cell and undergo cross presentation in
order to cause a significant T cell response, as was observed when the splenocytes were
fixed with glutaraldehyde. The cells that were fixed and not able to process the antigen
internally gave significantly less β-gal production compared to cells that were not fixed
and could process the antigen. This demonstrated that the SIINFEKL peptide was
actually undergoing cross-presentation.
Further studies of the HER2 protein to find specific peptides that can be directly
combined with MHC I and elicit a large cytotoxic T cell response could lead to an
effective vaccine targeting HER2 overexpressing tumor cells. The peptides naturally
formed by HER2 break down within the proteosome and lysosome could be examined
to determine which peptides are responsible for the pre-existing immunity found in
patients with HER2 overexpressing breast cancer. Peptides not normally formed by the
natural processing of HER2 could also be developed to elicit a new immune response to
less dominant HER2 antigens. These less dominant antigens would be less likely to
cause self-reactivity as suggested by Behrnard et al. (2002). There may also be a larger
repertoire of T cells specific to these less dominant antigens, since they are less likely to
be eliminated by negative selection to self antigens because the process is controlled by
the more dominant antigens (Behrnard et al., 2002). The self-reactivity observed as
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cardiac dysfunction in treatment with trastuzumab may be avoided through the design
of such a vaccine.
Glycosylation of the SIINFEKL peptide also appeared to slightly increase
presentation when compared to the non-glycosylated SIINFEKL at the highest
concentration. The β-gal production approached significance, with a p value of 0.078.
These observations demonstrated the combination of the increased cross-presentation
observed from the specific peptide along with glycosylation has the possibility to be
developed into a very effective vaccine agent to a target cytotoxic T cell response to a
tumor antigen.
The SIINFEKL peptide showed significant β-gal production using all methods of
presentation assayed (the RPMI method, super-activating with ionomycin and superactivating with interferon-γ), the super-activation with ionomycin method however was
the most effective. SIINFEKL presented by super-activation with ionomycin gave
significantly greater β-gal production compared to the other two methods. This also
demonstrated that the SIINFEKL peptide stayed complexed with the MHC I for an
extended period of time, since the B3Z cells were able to be activated to produce β-gal
48 hrs after the initial presentation of SIINFEKL. This method gives an important insight
into the formation of an ex-vivo vaccine against HER2. It suggests that supplementing
the vaccine with ionomycin when pulsing the antigen presenting cells with the desired
antigen may improve cross-presentation.
In another attempt to increase cross-presentation, the antigens were also
presented in the presence of GM-CSF. The EVI antigen conjugated to GM-CSF, EVIrGM,
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showed significant β-gal production compared to control at its highest concentration.
This was one of the first experiments performed for this project, and was most likely
before the B3Z cells become completely unresponsive to SIINFEKL presentation in the
MHC I due to a decrease in the number of TCRs. It was hypothesized that the GM-CSF
was able to bind the GM-CSF receptor on the cell surface, and the EVI was internalized
along with the GM-CSF and its receptor, thereby cross-presenting the EVI peptides.
While the EVIrGM was able to be cross presented, EVI supplemented with
GM-CSF, but not conjugated to it, did not give significant β-gal production. One study by
Knutson et al. (2002) attempted to use GM-CSF as an adjuvant to a HER2 vaccine. While
an initial immune response to the vaccine was detectable in two out of four patients,
the magnitude of the response was low and short lived. The immunity was not
detectable five months after the final vaccination. The observations of this study along
with the results of this project, support the further study of GM-CSF conjugation to an
antigen or peptide, rather than using it as an adjuvant. Conjugation to the peptide has
demonstrated to increase the amount of cross-presentation and elicit an improved
cytotoxic T cells response.
In an attempt to deliver the proteins directly into the cell and therefore increase
cross presentation, several transfection agents were assayed. The only one to
demonstrate significant increase in the presentation of SIINFEKL in the MHC I, as
measured by β-gal production in B3Z cells, was the Polyplus-transfection agent PULSin.
In combination with OVA, it was able to cause significantly greater β-gal production
when compared to the control. The PULSin agent also had no significant effect on cell
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viability when compared to the control. This demonstrated the possibility of
transfection agents as adjuvants to vaccine antigens to target the antigen for MHC I
presentation and activation of a cytotoxic T cell response.
Since the B3Z cells are specifically detecting SIINFEKL presented in the MHC I,
and not specific HER2 peptides, this may not be the best model system to represent a
HER2 antigenic vaccine. Other HER2 antigens may be processed by the splenocytes and
presented more efficiently then the SIINFEKL peptide but are not measured using the
B3Z assay. Since it has been demonstrated that only 6% of the possible SIINFEKL
peptides that can be formed from the proteolysis of OVA actually stay intact
(Rock et al., 2004), it is likely this same ratio would occur from processing EVI. While it
appears that most of the SIINFEKL peptide is destroyed during processing, there may be
other peptides within the HER2 portions of EVI that form at higher frequencies and are
being presented more efficiently by the splenocytes.
An advantage of this model is that it directly measures the ability of the
presented antigen to activate cytotoxic T cells. It is important for the desired antigen to
not only have efficient presentation, activating more antigen presenting cells, but the
presented antigen must also be able to activate specific cytotoxic T cells. In that
respect, the model is a good representation of the specific cytotoxic T cell populations
that exist within the immune system. It is also difficult to measure the specific antigen
presentation in the MHC I directly on the splenocytes, as demonstrated by the lack of
detection using the ELISA method. A model looking at IL-2 production by splenocytes
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presented with specific peptide antigens from HER2 may be a more effective
representation of a HER2 specific response.
The system has also been shown to assay the number of T cells activated, rather
than just increasing the amount of β-gal produced by single cells. Initial studies after
the formation of the B3Z cells showed that increasing stimulus increased the fraction of
cells expressing β-gal, but not the level of lacZ activity per cell
(Kattunen & Shastri, 1991). This gives the model physiological relevance as it mimics the
mounting of a cytotoxic T cell response by activating a population of specific T cells.
In conclusion, this project has provided insight into possible mechanisms for
increasing cross-presentation of tumor antigens. Glycosylation was demonstrated to be
an effective tool in increasing the cross presentation of the HER2 protein EVI. Other
approaches such as conjugation to GM-CSF or delivery of the protein into the cell by a
transfection agent demonstrate the possibility of improving antigen cross-presentation.
This project has also demonstrated the importance of finding a specific peptide to target
within an antigenic protein in order to more efficiently stimulate cross-presentation and
activation of cytotoxic T cells. The observations of this project provide insights into the
optimal antigenic conditions to consider when forming an immunogenic therapy for
HER2 overexpressing breast cancer.
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APPENDIX A:
LETTER OF APPROVAL FOR THE USE OF VERTEBRATE ANIMALS IN RESEARCH FROM
NORTHERN MICHIGAN UNIVERSITY’S DEAN OF GRADUATE STUDIES
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